11:51 am Wells Fargo reaches settlement of $81.6 mln w/ U.S. Trustee regarding Payment Change Notices for the bankruptcy court and escrow analyses for customers in Chapter 13 bankruptcy (WFC) :  

11:47 am Caesarstone announces that Kibbutz Sdot Yam requests to nominate two independent directors instead of two of the nominees recommended by the Co (CSTE) : Kibbutz Sdot Yam is encouraging Co to examine a share repurchase program, as well.

11:47 am Anavex (-14%) falls after Turing Pharma CEO Martin Shkrleli says the company 'looks worthless' (AVXL) :

• Short seller, Turing Pharma CEO and former RTRX CEO Martin Shkreli tweeted the following, which sent the stock down as much as 21%:
  • "@MartinShkreli: $AVXL looks worthless. Compound is uM for sigma receptor (meaningless affinity) and rest of muscarinic. Co. confused if its agonist or ant."
• Street sweeper was previously out cautious on the stock.
• AVXL was up listed to the NADAQ on October 26; the stock was trading under $1 at the beginning of the year.

11:32 am Goodyear Tire to redeem all of its outstanding $1 bln of 8.25% senior notes due 2020; results in interest expense savings of ~$31 mln in 2016 and beyond (GT) :

The redemption price will be 104.125% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to December 7, 2015.

• Co intends to use the net proceeds from its $1 bln offering of 5.125% senior notes due 2023, which closed November 5, together with current cash and cash equivalents, to fund the redemption. 
• The transactions will result in interest expense savings of ~ $31 mlnin 2016 and beyond.
• Co continues to expect interest expense to range between $415 mln and $425 mln for 2015.

11:02 am Agilent sign agreement w/ Thermo Fisher (TMO) to improve exchange instrument controls (A) :  

11:01 am TEGNA sells Clipped Magazine to Valassis (:VCI); terms not disclosed (TGNA) :  

11:01 am Dex Media enters into a forbearance agreement with lenders under its senior secured credit facilities (DXM) :

The agreement is effective through November 23, 2015. In addition, the Company announced it has received a term sheet and restructuring support agreement from the ad hoc committee of lenders holding more than 50% of its senior secured credit facilities.

• The Company and its advisors are reviewing the term sheet and RSA, and are continuing negotiations with the Company's lenders with a goal of agreeing on terms of a consensual restructuring. The Company's has a cash balance of $205.3 million

10:52 am S&P -11 slides to new session low of 2090 (SPY) : After stalling at the 62% retracement of Tues/Wed pullback at 2109 in early trade the index has edged back near a minor support at 2090 mentioned in The Technical Take. A secondary zone is at 2085/2084. The session low thus far is 2090 which also approximates its 50 ema hourly (2092) (see The Technical Take hourly chart). In order to neutralize the weaker intraday action off Tues/Thur highs the index will need to sustain a push back through 2096 and 2099.

10:50 am Investment Tech to sell its Calgary-based unit of investment research to Warburg Pincus for ~$120.5 mln in cash; expects to book a gain of $90-95 million after taxes (Shares halted) (ITG) :

Co has signed a definitive agreement to sell the Calgary-based unit of ITG Investment Research to Warburg Pincus.

• Under the terms of the agreement, Warburg Pincus will acquire the energy research group for $120.5 million in cash. ITG expects to book a gain of between $90 million and $95 million after taxes from this transaction. The transaction is expected to increase ITG's tangible book value by between $2.85 and $3.00 per share.
• ITG is currently evaluating alternatives for the use of the proceeds from this transaction, including strategic initiatives and share repurchases.

10:32 am Major averages drop to new session lows -- Dow -53, S&P -9, Nasdaq Comp -33 (:TECHX) : Sectors that have underperformed on a relative basis include: Semi SMH, Pharma PPH, Health XLV, Biotech IBB, Industrial XLI, Rail, Networking IGN.

10:28 am S&P -6 and Dow -41 join Nasdaq Comp -28 under Wed lows (:TECHX) :  

10:21 am Nasdaq Comp -20 slides below yesterday's trough, Dow -7 and S&P -3.2 set new session lows (:TECHX) :  

10:14 am Valeant Pharma (-18%) collapses to 2+ year low (VRX) :  

10:10 am S&P +0.7 rebound stalls at 62% retrace of Tues-Wed decline at 2109 and edges back (SPY) : Noted in The Technical Take that the S&P will need to initially sustain gains back above 2109 in order to improve the pattern off the high from Tuesday's (2116).

10:05 am Expedia sets a new session high of 139.04, its all time high from last week is at 139.58 (EXPE) :  

10:01 am Idera Pharma reports preclinical data for IMO-2125, showing potent and systemic anti-tumor activity in preclinical cancer models (IDRA) :

Co announced new preclinical data demonstrating potent and systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an anti-PD-1 monoclonal antibody.

• Idera scientists presented data providing evidence that intra-tumoral IMO-2125 administration changes the tumor microenvironment by increasing infiltration of tumor-infiltrating lymphocytes and by modulating gene expression of multiple checkpoints, including PD-L1. In the study, treatment with a combination of intra-tumoral IMO-2125 with anti-PD-1 antibody showed more potent anti-tumor activity than either agent alone, with potent anti-tumor activity observed on treated as well as distant tumors.
• Additionally, increased infiltration levels of TILs and increased PD-L1 and other checkpoint expression was observed in both treated and distant tumors.
• Idera expects to initiate the first clinical study of intra-tumoral IMO-2125 in combination with ipilimumab in patients with metastatic melanoma in the fourth quarter of this year

9:59 am Major averages edge slightly above opening highs -- Dow +43, S&P +4, Nasdaq Comp +7 (:TECHX) :  

9:42 am Market averages slip back off highs led by small-caps -- Russell 2000 -2.8, Nasdaq Comp -2, S&P +0.02, Dow +20 (:TECHX) :  

9:41 am Cellectis surges following 'encouraging data from one patient treated with 'off the shelf' UCART19 for Leukemia (ALL); competitors JUNO, KITE trading lower (CLLS) :

• Great Ormond Street Hospital (:GOSH) and University College London (:UCL) will present encouraging data from a first in man clinical use of UCART19, at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando during the poster session.
• GOSH has treated in June 2015 a young leukemia patient under a special license from the Medicines & Healthcare products Regulatory Agency(:MHRA) with Cellectis' TALENgene edited allogeneic UCART19 product candidate because no other therapies were available for refractory relapsed Acute Lymphoblastic Leukemia (ALL) following mismatched allogeneic stem cell transplantation.
• From Abstract:
  • 'She received a single dose (4.5x106/kg) of UCART19 T cells without any significant toxicity. To date there has been no significant perturbation of cytokine levels in peripheral blood, and no indication of cytokine release syndrome. Although profoundly lymphopenic, UCART19 T cells were detectable by qPCR in the circulation by day 14 and at increased levels in both blood (VCN 0.35) and marrow (VCN 0.22) on day 28. The patient exhibited signs of count recovery and the bone marrow, while hypoplastic, was in cytogenetic and molecular remission. Chimerism was 90% donor, and a clearly demarcated population (7%) of third party cells indicated persistence of UCART19. A residual persistence of 3% recipient cells in the marrow suggests that leukemic clearance was not mediated by transplant mediated alloreactivity. Within the short period of follow up available, our intervention comprising lymphodepletion and infusion of UCART19 T cells has induced molecular remission where all other treatments had failed. This first-in-man application of TALEN engineered cells provides early proof of concept evidence for a ready-made T cell strategy that will now be tested in early phase clinical trials.'
  • Link to abstract.
• "We are very glad for this young patient to have benefited from our highly innovative TALEN gene edited allogeneic CAR T therapy UCART19. We expect to accelerate our clinical development of TALEN gene-edited allogeneic CAR-T therapies to further confirm this encouraging clinical proof of concept." 

CLLS is attempting an 'off the shelf' CAR-T treatment while JUNO and KITE (both down 7%)treatments are patient specific.

9:40 am Relative sector performance (:TECHX) : Sectors displaying relative strength in early dealings include: Internet FDN, Social Media SOCL, Transports IYT, Pharma PPH, Trucking, Bank KBE, Technology XLK, Rail. Groups that are on the defensive are being led by: Steel SLX, Copper JJC, Crude Oil USO, Biotech IBB, Semi SMH, Gold Miners GDX, Mining XME, Home Const ITB, Oil Service OIH, Energy XLE.

9:39 am InfoSonics trades higher by 20%+ following earnings; co reported Q3 EPS of ($0.01) vs. ($0.04) in prior year period; revs rose 50% YoY to $12.2 mln - no ests (IFON) :  

9:39 am Opening Market Summary: Technology Sector Displays Opening Strength (:WRAPX) :

Equity indices began the trading day just above their flat lines before slipping into the red. As a result, the Dow, Nasdaq, and S&P 500 all trade near their unchanged levels with five sectors showing early gains.

The top-weighted technology sector (+0.4%) has shown relative strength at the start while the remaining groups hover closer to their flat lines. On the downside, energy (-0.6%) and materials (-0.5%) underperform with the energy sector following in the footsteps of crude oil. The energy component is currently lower by 0.6% at $46.05/bbl.

Elsewhere, Treasuries continue holding slim losses with the 10-yr yield up two basis points at 2.24%.

9:37 am Choppy start with a slightly firmer tone -- Dow +18, S&P +1, Nasdaq Comp +2.9 (:TECHX) :  

9:28 am Norwegian Cruise Line's NCL Corporation announces it will issue $500 mln in unregistered senior unsecured notes due 2020 (NCLH) : Co expects to use the net proceeds from the offering to redeem and discharge its outstanding 5% Senior Notes due 2018 and for other general corporate purposes, which may include debt repayment and/or opportunistic repurchases of common stock from time to time under its ongoing share repurchase program.

9:27 am First Data announces offering of $1.5 bln of senior secured notes due 2024 (FDC) :

Co intends to offer $750 mln aggregate principal amount of senior secured first lien notes due 2024 and $750 mln aggregate principal amount of senior secured second lien notes due 2024.

• The proposed offering of the Notes is part of a refinancing transaction that includes a proposed refinancing of First Data's senior secured term loan facility due March 2017 with the proceeds from incremental term loans with face amounts of $750 mln and 200 mln (estimated at $223 mln equivalent) under its senior secured term loan facility due July 2022.

9:27 am On the Wires (:WIRES) :

• Onconova Therapeutics (ONTX) announced that an abstract relating to the Company's Phase 2 clinical trial of oral rigosertib and azacitidine in higher-risk myelodysplastic syndromes and acute myeloid leukemia has been selected for oral presentation at the 57th American Society of Hematology Annual Meeting
• Immune Design (IMDZ) announced that preclinical research on G100, Immune Design's intratumoral TLR4 agonist-based product candidate, will be presented in an oral presentation at the 57th American Society of Hematology Annual Meeting
• Idera Pharmaceuticals (IDRA) announced that new data from the Phase 1/2 clinical trial for IMO-8400, a TLR 7,8 and 9 antagonist, being evaluated for the treatment of relapsed, refractory patients suffering from Waldenstrm's Macroglobulinemia, will be presented at the 2015 American Society of Hematology Annual Meeting
• Syneron Medical (ELOS) announced that the FDA has granted numerous additional indications for use of the CO2RE CO2 device. The new indications for use include gynecology applications, wrinkles, scars, and a wide range of dermatology and plastic surgery indications.
• Karyopharm Therapeutics (KPTI) will present additional data on Selinexor (KPT-330) activity in combination with other active agents across hematologic malignancies and new pipeline programs at ASH in Orlando.
• Atara Biotherapeutics (ATRA) announced that new data on two of its licensed clinical stage T-cell product candidates will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center during the 57th American Society of Hematology Annual Meeting
• TG Therapeutics (TGTX) announced that updated data for TG-1101, the Company's novel, glycoengineered anti-CD20 monoclonal antibody and TGR-1202 have been selected for presentation at the upcoming 57th American Society of Hematology Annual Meeting
• Curis (CRIS) announced that Phase 1 data for CUDC-907, Curis' proprietary dual histone deacetylase and phosphoinositide 3-kinase inhibitor will be presented at the 57th American Society of Hematology Annual Meeting

9:26 am On the Wires (:WIRES) :

• Nevada Gold & Casinos (UWN) announced that the Nevada Gaming Control Board has recommended approval of its application for a nonrestricted gaming license in conjunction with its pending acquisition of Club Fortune Casino in Henderson, NV.
• Amgen (AMGN) announced that a number of important abstracts and new data from the company's oncology portfolio, including Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), Nplate (romiplostim) and Neulasta (pegfilgrastim), are scheduled for presentation at the 57th American Society of Hematology Annual Meeting
• Aptose Biosciences (APTO) announced that preclinical data for its lead investigational anticancer therapeutic APTO-253 will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition. Co will present data demonstrating the ability of APTO-253 to kill acute myeloid leukemia cells in the majority of patient samples, with a trend toward correlation with baseline KLF4 expression level. Moreover, APTO-253 demonstrated enhanced killing ability of AML cells in patient samples when combined with either the BET inhibitor JQ1 or with the FLT3 inhibitor quizartinib.
• Acceleron Pharma (XLRN) will present data in six abstracts on the investigational protein therapeutics sotatercept, luspatercept and ACE-1332 at Ash in Orlando
• Alnylam Pharmaceuticals (ALNY) will present new results from ongoing clinical studies with two of its subcutaneously administered investigational RNAi therapeutics -- ALN-AT3 and ALN-CC5 -- at ASH in Orlando, Florida
• MEI Pharma (MEIP) published new data from the Company's Phase II clinical studies of the investigational drug Pracinostat in patients with previously untreated myelodysplastic syndrome and elderly patients with acute myeloid leukemia. Co also will present this data at ASH in Orlando
  
• Prothena Corporation plc (PRTA) announced that new preclinical data related to its NEOD001 program, health-related quality of life data in patients with AL amyloidosis, as well as follow-up case studies from patients in the NEOD001 Phase 1/2 multiple ascending dose trial, will be presented at the 57th Annual American Society of Hematology

9:26 am PAR Technology gapping up following Q3 results (PAR) : Q3 EPS $0.11 vs. $0.07 last year; re +10% to $58 mln (no ests).

9:26 am Dunkin Brands announces that 46 new restaurants will be developed in Georgia over the next several years by six franchisees; remains on track for 2015 restaurant develop. target (DNKN) :  

9:18 am Spirit Realty Capital reports FFO in-line, beats on revs; narrows FY15 FFO guidance; guides FY16 AFFO in-line (SRC) :

• Reports Q3 (Sep) funds from operations of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; revenues rose 10.6% year/year to $168.43 mln vs the $166.63 mln Capital IQ Consensus.
• Co narrows guidance for FY15, sees FFO of $0.86-0.87 ($0.85-0.87) prior vs. $0.83 Capital IQ Consensus Estimate.
• Co issues in-line guidance for FY16, sees AFFO of $0.88-0.91 vs. $0.88 Capital IQ Consensus Estimate.

9:15 am S&P futures vs fair value: +2.90. Nasdaq futures vs fair value: +9.00. (:WRAPX) :

The stock market is on track for a higher open with S&P 500 futures trading three points above fair value after climbing steadily since 4:00 ET. The early morning advance in futures has coincided with buying interest in Europe that has pushed markets in Germany and France higher by 1.0% apiece.

Index futures have backed away from their highs, continuing the retreat after the release of weekly initial claims and preliminary Q3 Productivity/Unit Labor Cost data. We can't say that the preliminary third quarter productivity report will put any real inflation scare in the Fed. It showed nonfarm business productivity increasing 1.6% quarter to quarter (Briefing.com consensus -0.2%) versus 3.5% in the second quarter. Output increased 1.2% while hours worked decreased 0.5%, marking the first decline in that series since the third quarter of 2009. Unit labor costs were up just 1.4% (Briefing.com consensus 2.2%).

Separately, initial claims for the week ending October 31 increased 16,000 to 276,000 (Briefing.com consensus 262,000) from an unrevised 2600,000 level in the prior week. There were no special factors influencing the jump in claims, which are still running at encouragingly low levels.

Unlike equity futures, Treasuries have ticked to lows following the data with the 10-yr yield up one basis points at 2.23%.

On the corporate front, Facebook (FB 109.39, +5.45) is on track to open higher by 5.2% in reaction to better than expected results while Qualcomm (QCOM 57.05, -3.21) has surrendered 5.3% in pre-market after below-consensus guidance overshadowed better than expected results.

9:11 am Tribune Publishing misses by $0.02, beats on revs; reaffirms FY15 guidance (TPUB) :

• Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.02 worse than the single analyst estimate of $0.14; revenues were unchanged from the year-ago period at $404.3 mln.
  • Advertising Revenues of $220 million, down slightly from the prior-year quarter and down 9.6%, excluding advertising revenues from the acquisition of The San Diego Union-Tribune;
  • Adj. EBITDA to $28 mln from $26 mln
• Co reaffirms guidance for FY15, sees FY15 revs of $1.645-1.675 bln vs. $1.66 bln Capital IQ Consensus; EBITDA $145-160 mln.

9:07 am EnteroMedics announces a $25 mln registered direct offering of senior amortizing convertible notes (ETRM) :

Co intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes.

• The Notes will be payable in monthly installments, will accrue interest at a rate of 7.0% per annum from the date of issuance and will mature 24 months after the initial closing.
• $1.5 mln of the Notes will be funded at the initial closing, and the balance will be funded in two tranches of $11.0 mln and $12.5 mln which are subject to the shareholders of the Co approving a reverse stock split of the Co's common stock and the approval of the issuance of the securities purchased by the Investors.

9:04 am Air Methods to acquire Tri-State Care Flight for $222.5 mln; expects deal to be immediately accretive to EPS (AIRM) :

Co has entered into a definitive agreement to acquire Tri-State Care Flight for $222.5 million. Tri-State generated net revenue of $81.5 million for the fiscal year ended Dec. 31, 2014.

• The transaction, which was unanimously approved by Air Methods' Board of Directors, is expected to be immediately accretive to Air Methods' earnings per share by greater than $0.20 in year one and by greater than $0.30 in year two.
• Air Methods expects to finance the acquisition through its credit facility, which was recently amended in August to provide for additional borrowing capacity.

9:03 am Rexahn Pharmaceuticals reports interim clinical data from its Phase IIa study of Archexin; dose levels tested to date appear to be safe and well tolerated (RNN) : Data from the ongoing Phase IIa clinical trial shows that Archexin, in combination with everolimus (Afinitor), appears to be safe and well tolerated at the doses tested to date. Co will present data on November 6, 2015 at the 14th International Kidney Cancer Symposium in Miami, Florida.

9:02 am Vringo provided an update on its global enforcement actions against ZTE (ZTCOF); plans to appeal the Tribunal's's judgment (VRNG) :

• The Tribunal found claims 1 to 11 and 13 of European patent 1,221,212 (the "EP 212 Patent") invalid and claims 1 to 5 and 10 to 15 of European patent 1,186,119 (the "EP 119 Patent") not implemented in the relevant standard. Vringo filed the lawsuit on April 2, 2013, based on particular information uncovered during a seizure to obtain evidence of infringement, known as a saisie- contrefaon, which was executed at two of ZTE's facilities in France. Vringo plans to appeal the Tribunal's's judgment; the appeal will be heard de novo.
• The EP 119 Patent has previously been found infringed by ZTE in Germany, where Vringo has enforced an injunction against ZTE. That injunction remains in place. Separately, the 119 patent was previously found valid by the European Patent office when validity its validity was challenged by Qualcomm (QCOM).

9:02 am Amec Foster Wheeler reports YTD results; lowers margin guidance; intends to cut dividend (AMFW) :

• Scope Revenue was 3,871m (2014 pro forma: 3,940m), 1.8% lower than last year's pro forma result, and 3.4% lower on a like-for-like basis. The order book stood at 6.5bn at the end of September, compared to 6.6bn at the half year. Trading margin trends have continued from the first half, with ongoing pricing pressure from customers and dilution from mix.
• For 2015, we expect to see a continuation of recent revenue trends - with growth in downstream and Middle Eastern Oil & Gas markets being offset by tougher conditions elsewhere, notably in upstream Oil & Gas and GPG.
  • Continue to expect 2015 underlying Scope Revenue to be modestly lower than last year's pro forma result. Based on current forecasts there is no longer any Y/Y net benefit from the translation of N American revenues into Sterling.
  • The changing mix of work in execution and continued customer pricing pressure, particularly in the Oil & Gas market, lead us to believe second half margins will be below those achieved in the first half of 2015. Cash generation remains solid, and conversion from Trading Profit is expected to remain in the historic range of 80-100%. Year-end net debt will be circa 1.1bn. This includes the impact of weaker H2 trading, adverse currency translation and assumes that the full payment for the Longview arbitration mentioned above is made.
• Looking ahead to 2016, expect to see the same trends impacting business as in 2015. Growth in the order book towards 7bn between now and the year-end will support low single digit Scope Revenue growth. The anticipated benefits of the additional cost saving measures referred to above will partially offset the continued customer pricing pressure and mix - leading to further modest Trading Margin dilution.
• Reduces dividend: The interim dividend of 14.8p per share, which was announced at the half year results, will be paid, as previously announced, on 5 January 2016 to shareholders on the register at the close of business on 27 Nov 2015. The Board now expects to recommend a final dividend for 2015 of circa 14.2p, half of the equivalent declared in 2014, at the full year results in March 2016. It is the current intention of the Board that ordinary dividends in 2016 will be approximately half that declared in 2014, with ~1/3rd paid at the interim, and 2/3rd as a final dividend.

9:02 am Pandora Media and Sony/ATV Music Publishing announce a multi-year licensing agreement for Sony/ATV's catalog of music (P) : Co and Sony/ATV Music PUblishing announce a multi-year licensing agreement for Sony/ATV's catalog of musical works. The public performance royalties Co also pays to rights holders of master recordings are not affected by this agreement.

9:01 am BioLineRx announces 'positive' results from the dose escalation part of BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia (BLRX) :

Results showed that BL-8040, as a single agent and in combination with Cytarabine, was safe and well tolerated at all doses tested up to and including the highest dose level of 1.5 mg/kg, with no major adverse events. The composite complete remission rate, including both complete remission and complete remission with incomplete blood count recovery (CRi), was 38% in subjects receiving only one cycle of BL-8040 treatment at doses of 1 mg/kg and higher (n=16). Patients included in this part of the study were patients that had undergone a significant number of prior treatment cycles or that were refractory to induction treatment.

• Treatment with BL-8040 had a triple effect on the leukemic cells. First, following only two days of monotherapy, BL-8040 triggered an average 40-fold mobilization of immature AML progenitor cells from the bone marrow to the peripheral blood, thereby sensitizing these cells to the Ara-C chemotherapy and improving its efficacy. Second, BL-8040 showed a direct and significant apoptotic effect on the immature leukemia progenitor cells in the bone marrow following the two days of monotherapy. Last, BL-8040 induced leukemia progenitor cells towards differentiation, as evidenced by a 58% median decrease in the number of bone marrow leukemia progenitor cells, along with a three-fold increase in differentiated granulocytes, in the bone marrow biopsy conducted on Day 3 of the treatment cycle prior to the Ara-C treatment, as compared to the biopsy performed at baseline.
• "In light of the encouraging results, we look forward to discussions with the regulatory authorities regarding the future development plan for AML. We currently anticipate reporting topline results from the full study by early next year."

9:01 am FTI Consulting announces $50 mln stock repurchase program (FCN) :  

9:00 am Jaguar Animal Health initiates a proof-of-concept study for SB-300 (JAGX) :

SB-300 is a pharmaceutical formulation of a standardized botanical extract from the Croton lechleri tree, which is sustainably harvested, for the treatment of gastrointestinal ulcers in horses.

• Additionally, Jaguar is planning trials to develop an equine-specific formulation of crofelemer for the treatment of diarrhea associated with acute colitis, a devastating and dehydrating condition that can lead to patient death in less than 24 hours.Crofelemer is an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. The Company intends to seek MUMS designation for the product.

8:59 am Alexandria RE announces an underwritten public offering of Senior Notes (ARE) : Co intends to use the net proceeds from this offering for the reduction of the outstanding balance on its unsecured senior line of credit.

8:57 am S&P futures vs fair value: +4.90. Nasdaq futures vs fair value: +11.50. (:WRAPX) :

The S&P 500 futures trade five points above fair value.

The Asian equity markets closed generally higher on a night that was very light in terms of macro data. Neither Japan nor China released any data points, but that did nothing to halt the upward momentum in the region. Chinese equities continued to outperform the region with the Shanghai closing nearly 2.0% higher on the day. There wasn't any pull back after yesterday's 4.0% gain, and the Mainland index got an additional sentiment boost following meetings between Chinese and Taiwanese officials that could potentially open up investment opportunities between the two nations. In Japan, the BoJ released the minutes from last week's meeting and the general take away was that the members continue to see progress within the domestic economy and expect inflation to pick up. This likely gave some perspective to investors for not adding any stimulus. With that said, the yen continued to see weakness overnight, which helped to propel the Nikkei 1.0% higher.

• In economic data:
  • Indonesia's Q3 GDP +3.2% (expected 3.3%)
  • Taiwan's October CPI +0.3% (expected 0.2%)

------

• Japan's Nikkei increased 1.0%. Japanese shares took off out of the gate and never looked back for the most part. The declines in the yen against the dollar after Janet Yellen's tone surrounding the liklihood of a Dec rate hike helped to provide a bid to the index. The Nikkei was also supported by following better than expected results from Japan Tobacco (+7.5%) and Fast Retailing's unit, Uniqlo (+4.9%). Softbank shares declined 1.2% today after it released earnings after the market closed yesterday.
• Hong Kong's Hang Seng was unchanged today. The market was held in check today, with a mixed board across the components. Some of the notable movers to the upside were Ping AN +2.8%, and HSBC +1.9%, and China Life +1.0%. Some of the notable movers to the downside were Sino Land -2.7%, Want Want China -1.7%, and Hang Seng Bank -1.0%.
• China's Shanghai Composite rose 1.8%, extending gains and moving back into bull market territory after it has moved up 20% from the summer lows. The telecom sector saw robust gains to give the index support after reports suggested the state was considering consolidating the sector. As such, China Unicom soared 10%, hitting its daily limit up following the news.

Major European indices trade mostly higher while UK's FTSE (-0.1%) underperforms. The Bank of England made no changes to its policy stance, keeping its interest rate and purchase program unchanged at their respective 0.50% and GBP375 billion. Furthermore, the central bank's policy minutes revealed no change in attitude among participants with eight members calling for no change to policy while one member remained in the rate hike camp.

• Investors received several data points:
  • Eurozone September Retail Sales -0.1% month-over-month (expected 0.2%; prior 0.0%); +2.9% year-over-year (consensus 3.0%; prior 2.2%). Separately, Retail PMI 51.3 (prior 51.9)
  • Germany's September Factory Orders -1.7% month-over-month (expected 1.0%; previous -1.8%)
  • UK's October Halifax House Price Index +1.1% month-over-month (consensus 0.6%; prior -0.9%); +9.7% year-over-year (consensus 9.5%; last 8.6%)
  • Swiss October CPI +0.1% month-over-month (expected 0.0%; prior 0.1%); -1.4% year-over-year, as expected (prior -1.4%). Separately, Q4 SECO Consumer Climate -18 (expected -14; previous -19)

------

• UK's FTSE hovers just below its unchanged level with drugmakers showing relative strength after AstraZeneca reported better than expected results. The stock has spiked 4.2% while peers Hikma Pharmaceuticals and Shire hold respective gains of 2.4% and 1.9%. On the downside, energy and mining names lag with Anglo American, Randgold Resources, BP, and Royal Dutch Shell down between 2.1% and 6.6%.
• Germany's DAX trades up 0.9% with Adidas surging 8.1% in reaction to better than expected results. Most other index components also trade in the green while five listings trade in the red with Volkswagen down 3.4%.
• In France, the CAC has climbed 1.0%. Societe Generale leads with a 6.9% gain after reporting above-consensus results while Credit Agricole is down 5.8% after missing estimates. Elsewhere, consumer names outperform with Danone, L'Oreal, and Kering up between 1.6% and 2.0%.

8:56 am South Jersey Inds reports Q3 (Sep) results; reaffirms FY15 EPS guidance (SJI) :

• Reports Q3 (Sep) loss of $0.07 per share, may not be comparable to the Capital IQ Consensus of $0.11. While the thirdquarter is generally a lower producing period, these results were furtherhindered by increases in write-offs for uncollectible accounts in our utility,as well as increased post-retirement account expenses. Lower levels ofinvestment tax credits associated with solar project development alsocontributed to the year-over-year variance.
• Co reaffirms guidance for FY15, sees EPS of $1.49-1.54 vs. $1.50 Capital IQ Consensus Estimate.

8:55 am On the Wires (:WIRES) :

• Signal Genetics (SGNL) announced that a peer-reviewed paper highlighting the clinical utility of MyPRS in the everyday management of patients with multiple myeloma, was published on-line in the journal Leukemia.
• ChemoCentryx (CCXI) announced data presentations from two of its chemoattractant receptor programs at the American Society of Nephrology Kidney Week Annual Meeting. The presentation includes a description and analysis of the statistically significant improvement in levels of protein in the urine across the entire Phase II patient population tested. CCX140 appeared to be well tolerated, with a low overall dropout rate over the 52-week treatment period
• Merck (MRK) announced that its collaborative partner Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology and the Association for Rheumatology Health Professionals 2015 Annual Meeting
• Halozyme Therapeutics (HALO) dosed the first patient w/ its IND, PEGPH20 in combination with Merck's (MRK) Keytruda in a clinical trial to determine the maximum tolerated dose of PEGPH20 and antitumor activity of the combined therapies.
• Amedica Corporation (AMDA) entered into a multi-year private label agreement with a regional medical device company that markets solutions for the treatment of spinal disorders. Co will provide sterile-packed silicon nitride spinal interbody fusion devices to be available in key domestic markets.
• Live Ventures (LIVE) announced that its wholly owned subsidiary, ModernEveryday.com, has expanded its distribution network into the Japanese market
• Scientific Games Corporation (SGMS) was awarded 5-year contract Arizona lottery's integrated lottery gaming system

8:55 am European Markets Update: FTSE -0.1%, DAX +0.9%, CAC +1.0% (:SUMRX) :

Major European indices trade mostly higher while UK's FTSE (-0.1%) underperforms. The Bank of England made no changes to its policy stance, keeping its interest rate and purchase program unchanged at their respective 0.50% and GBP375 billion. Furthermore, the central bank's policy minutes revealed no change in attitude among participants with eight members calling for no change to policy while one member remained in the rate hike camp.

• Investors received several data points:
  • Eurozone September Retail Sales -0.1% month-over-month (expected 0.2%; prior 0.0%); +2.9% year-over-year (consensus 3.0%; prior 2.2%). Separately, Retail PMI 51.3 (prior 51.9)
  • Germany's September Factory Orders -1.7% month-over-month (expected 1.0%; previous -1.8%)
  • UK's October Halifax House Price Index +1.1% month-over-month (consensus 0.6%; prior -0.9%); +9.7% year-over-year (consensus 9.5%; last 8.6%)
  • Swiss October CPI +0.1% month-over-month (expected 0.0%; prior 0.1%); -1.4% year-over-year, as expected (prior -1.4%). Separately, Q4 SECO Consumer Climate -18 (expected -14; previous -19)

------

• UK's FTSE hovers just below its unchanged level with drugmakers showing relative strength after AstraZeneca reported better than expected results. The stock has spiked 4.2% while peers Hikma Pharmaceuticals and Shire hold respective gains of 2.4% and 1.9%. On the downside, energy and mining names lag with Anglo American, Randgold Resources, BP, and Royal Dutch Shell down between 2.1% and 6.6%.
• Germany's DAX trades up 0.9% with Adidas surging 8.1% in reaction to better than expected results. Most other index components also trade in the green while five listings trade in the red with Volkswagen down 3.4%.
• In France, the CAC has climbed 1.0%. Societe Generale leads with a 6.9% gain after reporting above-consensus results while Credit Agricole is down 5.8% after missing estimates. Elsewhere, consumer names outperform with Danone, L'Oreal, and Kering up between 1.6% and 2.0%.

8:50 am Gapping down (SCANX) : Gapping down
In reaction to earnings/guidance: XENT -23.9%, GUID -21.5%, FEYE -18.4%, BLUE -17.9%, ALR -14.5%, CSLT -14.2%, LCI -14.1%, AVG -14%, FRSH -12%, ACLS -11.8%, MGA -8.2%, G -7.4%, CF -7.3%, WAC -7.3%, WFM -7.2%, ETP -7.1%, EPAM -6.9%, TUMI -6.2%, ENVA -5.8%, LPSN -5.4%, MBI -5.4%, CSTM -5.4%, ANDE -5.1%, QCOM -5%, PDLI -4.7%, ESI -4.7%, ATHM -4.6%, ZUMZ -4.1%, RLYP -3.4%, XNPT -3.3%, SEAS -3.2%, HOLX -3.1%, RGR -2.8%, VVUS -2.6%, RIG -2.6%, MET -2.6%, VER -2.3%, SBAC -2.2%, TWO -2.2%, FNHC -1.9%, HDP -1.8%, FUEL -1.8%, (appoints Randy Wootton as CEO), BKCC -1.7%, SFY -1.7%, SPPI -1.1%, (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), INOV -1.1%, SQNM -1.1%, WMGI -1%, PEIX -1%

Other news: LCI -14.1% (discloses update on pending acquisition of Kremers Urban Pharmaceuticals regarding transition of one of its customers), AVG -14% (announces that John Little will transition from his role as Chief Financial Officer), SABR -1.7% (announces the secondary public offering of 30 mln shares of common stock by existing stockholders; Co will repurchase ~$100 mln of the 30 mln shares from the underwriter), SPPI -1.1% (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), TVPT -0.9% ( files mixed securities shelf offering), VLRS -0.9% (reported October traffic)

Analyst comments: AVP -2.3% (downgraded to Sell from Neutral at UBS ), DYAX -0.9% (downgraded to Hold from Buy at Needham)

8:48 am Kimco Realty Correction: Beats FFO by $0.03; raises FFO guidance (KIM) :

• Reports Q3 (Sep) funds from operations of $0.40 per share, $0.03 better than the Capital IQ Consensus of $0.37; revenues rose 13.0% year/year to $288.32 mln vs the $289.03 mln Capital IQ Consensus.
• Co raises FY15 FFO to $1.54-1.57 from $1.52-1.56, may not compare to $1.45 Capital IQ Consensus
  • Last night we reported adj. FFO; that comment has been removed.

8:47 am Gapping up (SCANX) : Gapping up
In reaction to earnings/guidance: CCRN +24.4%, PCOM +21%, SD +16.9%, CDXS +16.4%, MHGC +14.8%, BOJA +13.6%, AHS +13.4%, SCSS +13.1%, SEDG +10.9%, FLT +8.3%, MRIN +8.1%, HABT +8%, GDDY +7.7%, MELI +7.5%, TXMD +7%, HDSN +5.9%, POWR +5.8%, BRKR +5.7%, LNTH +5.7%, XPO +5.5%, ACAS +5.1%, OSUR +4.9%, FB +4.8%, MATR +3.7%, HUBS +3.6%, KW +2.9%, COHR +2.8%, LFVN +2.8%, AHT +2.2%, BREW +2.1%, MCHP +2%, OME +1.8%, CLR +1.8%, CTL +1.6%, SUN +1.5%, UHAL +1.4%, IMH +1.3%, TNH +1.2%, WSR +1.1%, PSEC +1%

M&A news: SD +16.9% (acquired the assets of EE3 for $190 mln in cash, adds 136,000 largely contiguous net acres and multiyear niobrara shale drilling inventory in North Park Basin, Colorado; co also reported earnings),AWAY +23.3% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln), EXPE +4.1%

Other news: NRX +13.3% (announced successful results from a preclinical toxicity study of intravenous Pyridorin),ETRM +10.3% (presents two year follow up results from the ReCharge Study of vBloc Neurometabolic Therapy in obesity ),OASM +4.8% (confirms the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane),INO +4.7% (reports interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses),RXII +4.5% (initiates a Phase 1/2 clinical trial of RXI-109, as a potential treatment to prevent the progression of retinal scarring),EXPE +4.1% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln),ADSK +3.7% (: Sachem Head Capital Management discloses 5.7% active stake in 13D filing; Sachem Head intends to engage with management ),GLUU +3.2% (Integrated Core Strategies (Millennium International Management) discloses 5.2% passive stake in 13G filing),.

Analyst comments: ISIS +3% (upgraded to Overweight from Neutral at Piper Jaffray), MCHP +2% (upgraded to Buy from Neutral at B. Riley & Co),SHOP +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)

8:46 am Eyegate Pharmaceuticals announces interim data for its EGP-437 ophthalmic solution in Macular Edema patients; suggests that iontophoresis can deliver EGP-437 to the back of the eye (EYEG) :

Co announces interim data on the effects of iontophoretic delivery of their EGP-437 ophthalmic solution on Macular Edema patients that suggests that iontophoresis can non-invasively deliver EGP-437 to the back of the eye.

• The non-invasive delivery of EGP-437 has demonstrated a positive response in some patients with macular edema.
• A positive response was observed in some of the patients, with pseudophakic eyes responding better than phakic eyes. Additionally, the investigational therapy showed no serious treatment emergent adverse effects including no increase in ocular pressure even at three times the iontophoretic dose that was used for the Co's Phase 3 non-infectious anterior uveitis trial.
• Co expects additional data from the extension of trial in mid-2016.
• The extension stage of the trial will recruit an additional 15 patients with a modified dosing regimen, 3 consecutive days at the same iontophoretic dosage.
• The extension of the trial will also evaluate the efficacy of iontophoretic EGP-437 in phakic versus pseudophakic eyes to collect additional data on the differences in the responses of both types of eyes.
• The extension of the trial is expected to begin by the end of 2015.

8:44 am Boulder Brands beats by $0.02, beats on revs; reaffirms FY15 EPS guidance (BDBD) :

• Reports Q3 (Sep) earnings of $0.08 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.06; revenues fell 0.7% year/year to $132.9 mln vs the $130.17 mln Capital IQ Consensus.
• Co reaffirms guidance for FY15, sees EPS of $0.20-0.25 vs. $0.20 Capital IQ Consensus Estimate.

8:44 am TCP Capital reports Q4 net invest income of $0.40, a penny above the CapIQ Consensus est; declares Q4 dividend of $0.36 per share (TCPC) :  

8:40 am Market View: Dec. E-mini stock-index futures remain bid but are well off better levels here following the 8:30 am ET economic data points (:TECHX) :

• ESz5 now @ 2101.25 +6.50
  
  
• NQz5 now @ 4720.00 +10.50
  
  
• YMz5 now @ 17839 +52

8:39 am Koppers Holdings beats by $0.01, misses on revs; reaffirms FY15 EPS guidance, revs guidance (KOP) :

• Reports Q3 (Sep) earnings of $0.66 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.65; revenues fell 1.4% year/year to $433.8 mln vs the $454.72 mln two analyst estimate.
• Co reaffirms guidance for FY15, sees EPS of $1.65-1.75, excluding non-recurring items, vs. $1.73 Capital IQ Consensus Estimate; sees FY15 revs of approx $1.7 bln vs. $1.68 bln Capital IQ Consensus Estimate.

8:38 am Actua beats by $0.05, reports revs in-line; improved to FY15 EPS above consensus, lowered top end of revenue guidance, below consensus (ACTA) :

• Reports Q3 (Sep) loss of $0.07 per share, $0.05 better than the Capital IQ Consensus of ($0.12); revenues rose 63.9% year/year to $34.1 mln vs the $33.88 mln Capital IQ Consensus.
• Co issues guidance for FY15, improved to $(0.36)-(0.33) vs. ($0.38) Capital IQ Consensus Estimate, from ($0.40)-(0.36);lowered top end of FY15 revs to $133-134 vs. $135.58 mln Capital IQ Consensus Estimate, from $133-138 mln.

8:37 am Wausau Paper reports EPS in-line, revs in-line (WPP) :

• Reports Q3 (Sep) earnings of $0.05 per share, in-line with the single analyst estimate of $0.05; revenues were unchanged from the year-ago period at $95.45 mln.
• Wausau Paper is in the process of being acquired by SCA Americas.

8:37 am Opko Health to present data suggesting that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to control elevated iPTH (OPK) : Co to present additional Phase 3 data on Rayaldee at Kidney Week 2015 on Thursday, November 5 at 10 AM PST. 

8:35 am Medical Properties Trust beats by $0.01, beats on revs (MPW) :

• Reports Q3 (Sep) funds from operations of $0.32 per share, $0.01 better than the Capital IQ Consensus of $0.31; revenues rose 41.8% year/year to $114.6 mln vs the $110.81 mln Capital IQ Consensus.
• Normalized FFO is expected to range between approximately $1.30 and $1.33 on an annual run-rate basis. This estimate does not include potential earnings from MPT's equity investment in Capella.

8:35 am Pericom Semi's Board sends letter to shareholders urging them to vote for the proposed merger with Diodes Inc. (DIOD), cautions of risks in the offer from Montage Technology (PSEM) :  

8:34 am AMC Networks beats by $0.24, beats on revs (AMCX) :

• Reports Q3 (Sep) earnings of $1.09 per share, excluding non-recurring items, $0.24 better than the Capital IQ Consensus of $0.85; revenues rose 21.7% year/year to $632.2 mln vs the $604.8 mln Capital IQ Consensus.
• "AMC Networks had outstanding performance in the quarter, with significant increases in net revenues and operating cash flow driven by the continued popularity of our networks' original programming, notably BBC AMERICA's "Doctor Who" and AMC's newest original series, "Fear the Walking Dead," which premiered to record numbers, becoming the biggest series debut in cable television history."
• "We continue to invest in our international business, growing our portfolio of strong local brands and launching the AMC brand into new markets. We are confident our approach to creating great content and building networks with distinct brands that resonate with viewers will continue to drive our performance over the near- and long-term and deliver value for our shareholders."

8:33 am Aqua Metals closes on $10 mln loan for the development of its first AquaRefinery (AQMS) :

Co announces a $10 mln loan from Green Bank for the development of its first AquaRefinery.

• The loan will provide non-dilutive capital to finance the growth of Co and enhance the development of the Co's first AquaRefinery currently under construction in the Tahoe-Reno Industrial Center in Nevada.

8:33 am Stellar Biotechnologies commences trading on the Nasdaq Capital Market today following successfull uplisting (:SBOT) :  

8:33 am CymaBay Therapeutics announces results from two Phase 2 studies of Arhalofenate at the American College of Rheumatology Annual Meeting (CBAY) :

• One was a double-blind, placebo controlled phase 2b study which enrolled 239 subjects with gout, hyperuricemia and a history of flares. The primary efficacy endpoint , a comparison of flare rates between the arhalofenate 800 mg and allopurinol 300 mg groups, was met with arhalofenate showing a 46% reduction in flare rate. Additional key outcomes included a 41% lower flare rate for the arhalofenate 800 mg group compared to placebo and reductions in sUA for the arhalofenate 600 and 800 mg groups at 12 weeks vs. placebo that were statistically significant. Arhalofenate was well tolerated and appeared safe.
• The second was a single-center, open label phase 2 study that enrolled two cohorts of gout patients with hyperuricemia. Cohorts were administered arhalofenate 600 or 800 mg as monotherapy, followed by combination with febuxostat, and finally by febuxostat as monotherapy. The combination of febuxostat and arhalofenate demonstrated a potent serum uric acid lowering activity. For the highest dose combination, a 63% reduction from baseline in sUA was observed resulting in 100 and 79% of patients achieving a sUA

8:32 am U.S. Physical Therapy misses by $0.01, reports revs in-line (USPH) :

• Reports Q3 (Sep) earnings of $0.47 per share, $0.01 worse than the Capital IQ Consensus of $0.48; revenues rose 8.1% year/year to $84 mln vs the $83.66 mln Capital IQ Consensus.
• Same store visits increased 3.3% for de novo and acquired clinics open for one year or more and same store revenue increased 2.5% as the average net rate per visit decreased by $0.84.
• The gross margin for the third quarter of 2015 was $18.9 mln or 22.5%, as compared to $18.8 mln or 24.1% in the 2014 period.
• Total clinic operating costs were $65.2 mln, or 77.5% of net revenues, in 3Q15, as compared to $59.0 mln, or 75.9% of net revenues, in the 2014 period. The increase was primarily attributable to $5.1 mln in operating costs of new clinics opened or acquired in the past 12 months.

8:32 am S&P futures vs fair value: +5.60. Nasdaq futures vs fair value: +11.30. (:WRAPX) :

The S&P 500 futures trade six points above fair value.

The latest weekly initial jobless claims count totaled 276,000 while the Briefing.com consensus expected a reading of 262,000. Today's tally was above the unrevised prior week count of 260,000. As for continuing claims, they rose to 2.163 million from 2.146 million.

Unit labor costs increased 1.4% during the third quarter, which was lower than the 2.2% increase that had been anticipated by the Briefing.com consensus. During the same period, productivity increased 1.6%, according to the preliminary reading while the consensus expected a decrease of 0.2%.

8:31 am Iteris Holdings awarded $8.9 mln 511 traveler information contract by the San Francisco Bay area MTC (ITI) :

Co receives the 511 San Francisco Bay Area System Integrator, Data Management & Dissemination, and Interactive Voice Response Phone System service contract by the Metropolitan Transportation Commission.

• Work on the four-year, $8.9 mln service agreement commences immediately.

8:31 am On the Wires (:WIRES) :

• bluebird bio (BLUE) will present data from its ongoing clinical studies of LentiGlobin BB305 in beta-thalassemia major and severe sickle cell disease at the American Society of Hematology Meeting. Co will also present preclinical data from its lead oncology program, bb2121.
• Semtech Corporation (SMTC) LoRa technology has been selected by Tata Communications for its deployment of an Internet of things network in cities in India.
• Lpath (LPTN) announced it will present data from the Nexus Phase 2 study of iSONEP at the American Academy of Ophthalmology Meeting in Las Vegas
• ESSA Pharma (EPIX) has been issued a 'no objection letter' for the Clinical Trial Authorization application that Co has submitted from Health Canada. The letter will allow ESSA to include Canadian sites in its ongoing Phase 1/2 clinical study of its novel agent, EPI-506. Enrollment in the clinical trial in Canada is expected to commence in the next few weeks.
• ChromaDex (CDXC) announced it has entered into a joint development agreement with The Procter & Gamble Company (PG). Under the terms of the agreement, ChromaDex will provide P&G exclusivity to proprietary ingredients for use in P&G branded products. P&G will make an undisclosed up-front payment to ChromaDex as well as other payments based on achievement of various milestones.
• MarineMax (HZO) announced that it has expanded its financing facility to provide for borrowings of up to $260 million from the previous limit of $235 million. The expanded facility has a three-year term, expiring in October 2018, and it has two, one-year options for renewal

8:30 am Ecolab's Nalco Champion subsidiary acquires Ultra Fab Industries; terms not disclosed (ECL) : Ultra Fab Industries Ltd. is a privately held company based in Calgary, Canada, that designs and manufactures customized solutions and specialized chemical injection systems for the oil and gas industry.

8:29 am Transmontaigne Partners misses by $0.17, misses on revs (TLP) :

• Reports Q3 (Sep) earnings of $0.37 per share, $0.17 worse than the Capital IQ Consensus of $0.54; revenues rose 4.5% year/year to $37.3 mln vs the $38.32 mln Capital IQ Consensus.

8:25 am Goldman Sachs BDC amends its senior secured revolving credit agreement (GSBD) :

Aggregate commitments under the Revolving Credit Facility increased from $560 million to $570 million. 

• The Revolving Credit Facility includes an accordion feature that permits the Company, under certain circumstances, to increase its total borrowing capacity to a maximum of $1.0 billion. The stated interest rate on the RevolvingCredit Facility was changed from LIBOR plus 2.25% to either LIBOR plus 1.75% or LIBOR plus 2%

8:24 am European Yields (BONDX) :

Gilt Yields Fall on Bank of England's Dovishness

• European government bonds were a mixed bag today, with England, France, and Portugal seeing lower yields while Germany and Spain's edged higher. Since the end of the ECB rally, when Mario Draghi sent government debt soaring as he said all options for further monetary easing were on the table, the 10-year German Bund yield has moved 19 bps higher. The jump in yields for France, Italy, and Spain has been similarly dramatic. While an expansion/extension of the ECB's EUR 1.1 tln asset purchase program or a reduction in the deposit rate from its current level of -0.2% should stimulate the economy and eventually lead to higher yields, this bond sell-off is sooner than one might have predicted. To our minds, it is more likely a function of the sell-off in the Treasury market, and European sovereign has been swept up in the storm. The result may be that the European Central Bank has difficulty boosting growth in its economy as long as the Federal Reserve is in a tightening cycle, particularly if EUR/USD fails to fall significantly further. It is just that currency adjustment that many hedge funds and analysts at Goldman Sachs are expecting into year-end
  
• Eurozone retail sales fell 0.1% m/m in September, confounding economists' expectations for a modest gain. Retail sales were unchanged in August
  
  • European Central Bank President Mario Draghi said this morning that "We must consider if weaker global environment impacts ability to return to price stability"
    
  • In Germany, factory orders unexpectedly fell 1.7% m/m in September after declining 1.8% in August
    
• The Bank of England voted 8-1 in favor of holding its main policy rate at 0.5%
  
  • The 2015 and 2016 GDP growth forecasts were both lowered to 2.7% and 2.5%, respectively
    
  • The central bank also forecast that consumer prices would grow at less than 1% until H2 2016 in its quarterly inflation report, while also citing downside risks to the outlook
    
  • The U.K.'s Halifax House Price Index rose a better-than-expected 1.1% m/m in October after falling 0.9% in September. The index was up 9.7% y/y
    
• Switzerland's SECO Consumer Climate Index rose less than expected to -18 in the fourth quarter from -19 in Q3
  
  • The Swiss CPI unexpectedly rose 0.1% in October after gaining the same amount in September
    
• Yield Check:
  
  • France, 10-yr OAT: -2 bps to 0.95%
    
  • Germany, 10-yr Bund: +1 bp to 0.61%
    
  • Greece, 10-yr note: +1 bp to 7.63%
    
  • Italy, 10-yr BTP: unch at 1.57%
    
  • Portugal, 10-yr note: -2 bps to 2.53%
    
  • Spain, 10-yr ODE: +2 bps to 1.77%
    
  • U.K., 10-yr Gilt: -3 bps to 1.97%

8:24 am Bluebirdbio sells off on updatied trial data at ASH (abstract); two beta0-beta0 genotypes beta-thal patients needed a blood transfusion, one remains independent -- call at 8:30 (BLUE) :

• "We are pleased to see a median HbAT87Q level of 5.2 g/dL in the seven Northstar patients with beta-thalassemia major of all genotypes followed for six months or more, as this represents a substantial proportion of their total hemoglobin. It is exciting that transfusion independence has been achieved in all of our patients with beta-thalassemia major with non-0/0 genotypes followed for at least six months in Northstar and HGB-205. Varying degrees of transfusion reduction have been observed in patients with 0/0 genotypes. As would be expected, longer follow-up is required to assess the extent of HbAT87Q production and the impact on transfusion requirements in these patients with 0/0 genotypes since they produce no functional beta-globin at baseline. Turning to sickle cell disease, our first treated patient is producing increased levels of HbAT87Q since we last reported on this study in June. HbAT87Q represented 48 percent of total hemoglobin at nine months post-infusion, and the patient remains transfusion independent without sickle cell-related adverse events as of the data cut-off. These results support the transformative potential of gene therapy, and we look forward to sharing more data at ASH."
• HGB-204 Abstract 201:
  • All four non-0/0 subjects have been transfusion-free for at least 90 days, with a median of 287 days transfusion-free (range: 171 to 396 days).  
  • Two of the 0/0 subjects have received a single transfusion post-discharge, and one remains transfusion-dependent.
• Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector (Abstract #202)
  • The subject with severe SCD is producing ~ 51.5% anti-sickling hemoglobin (48 percent HbAT87Q, 1.8 percent HbF, 1.7 percent HbA2) at nine months post-infusion.
  • The subject with severe SCD remains free of transfusions.
  • The subject with severe SCD has not had a post-treatment hospitalization for a disease-related event despite ceasing chronic transfusions on Day +88.
  • Both subjects with beta-thalassemia major have remained transfusion-free for at least 15 months post-infusion, with consistent expression of HbAT87Q -- both subjects are 0/E genotype

8:21 am Aegerion Pharma postpones today's earnings call, will now host its Q3 call and business update on Monday after the close (AEGR) :  

8:20 am Brookfield Infrastructure confirms it has acquired a 14.9% stake in Asciano Limited (AANOF) for ~$1.2 bln (BIP) : Subject to agreeing to a bid implementation agreement with Asciano, which is being progressed, Brookfield Infrastructure intends to make a takeover offer for Asciano for the same consideration as the 'standard consideration' under the existing scheme of arrangement announced on August 17, 2015. The takeover offer would be subject to a 50.1% minimum acceptance condition and would have similar conditions(1) to the scheme of arrangement, including ACCC merger clearance. BIP has also entered into arrangements giving it economic interests in a further approximately 4.3% of Asciano.

8:19 am Yulong Eco-Materials expects to report that Q1 net income will increase by ~50% y/y to ~$3.5 mln (YECO) : The main reason for this anticipated improvement is the estimated $2 million in fiscal 2016 Q1 revenue contributed by the company's waste hauling and recycling division, which commenced operations in the fourth quarter of fiscal 2015. The gross margin on this revenue is about 60 percent, the highest of all company divisions. Yulong expects to report that its overall fiscal 2016 Q1 revenue grew by about 14 percent to over $13 million.

8:16 am adaptimmune therapeutics reports data from a clinical study of ny-eso affinity enhanced t-cell therapy, showing a 50% response rate in Synovial Sarcoma (ADAP) :

Co presents updated data on its lead clinical program, an affinity enhanced T-cell receptor therapy targeting the NY-ESO-1 cancer antigen in synovial sarcoma, at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer.

• In the primary efficacy analysis, 50 percent of synovial sarcoma patients receiving Adaptimmune's affinity enhanced T-cell therapy targeting NY-ESO responded, and 75 percent remain alive and on long term-follow up. Sixty percent of patients receiving the target dose responded, and 90 percent remain alive and on long term-follow up
• Adaptimmune's affinity enhanced T-cell therapy targeting NY-ESO in multiple myeloma generated responses that were better than expected for autologous stem cell transplant alone, despite the patients having advanced stage disease with 60 percent of patients having tumor chromosomal abnormalities.
• Authors also stated that Seventy-five percent of all subjects who received any dose of NY-ESO-1 T cells - and 90 percent of subjects who received the minimum intended cell dose - are alive and on long term follow-up. Forty-two percent of patients who received any dose have survival data beyond one year.

8:16 am EZchip reports in-line Q3; guides Q4 revs below consensus; CEO urges shareholder to approve acquisition by MLNX for $25.50 (EZCH) :

• Reports Q3 (Sep) earnings of $0.36 per share, in-line with the Capital IQ Consensus of $0.36; revenues rose 60% year/year to $30.7 mln vs the $30.5 mln Capital IQ Consensus.
• Co issues downside guidance for Q4, sees Q4 revs of ~$25 mln vs. $33.12 mln Capital IQ Consensus, due to near-term inventory adjustments across several key customers that are serving the carrier networking space. The Company believes that this slowdown does not reflect the long-term outlook for the Company's performance nor the underlying business.
• CEO: "As EZchip's founder and largest individual shareholder, I, together with the entire EZchip Board, urge shareholders to vote FOR the transaction with Mellanox (MLNX) at the upcoming Annual General Meeting."

8:15 am Apache beats by $0.35, misses on revs (APA) :

• Reports Q3 (Sep) loss of $0.05 per share, excluding non-recurring items, $0.35 better than the Capital IQ Consensus of ($0.40); revenues fell 56.5% year/year to $1.5 bln vs the $1.58 bln Capital IQ Consensus.

• Apache operated an average of 28 rigs worldwide and drilled 111 gross operated wells, 92 of which were North American onshore.

2015 outlook and guidance update:

• Despite a significantly reduced capital program, production volumes have shown tremendous resiliency; as a result, Apache is again raising 2015 production-guidance ranges.
• The co is increasing its full-year 2015 North American onshore production guidance to a range of 307,000-309,000 boe per day, which is up from prior guidance of 305,000 to 308,000 boe per day. On a pro forma basis, this represents more than 2% year-over-year growth.
• Internationally, Apache delivered strong third-quarter production growth through record production efficiency in the North Sea, sustained solid base performance and better-than-expected contributions from new wells.
• These results enable the company to raise its full-year 2015 international and offshore pro forma production guidance to 172,000-174,000 boe per day, up from a previous range of 164,000 to 168,000 boe per day. This represents substantial year-over-year growth of 10-12%.

8:14 am Winthrop Realty Trust declares liquidating distribution of $1.00 per common share; co is liquidating and winding down pursuant to a plan of liquidation (FUR) :  

8:10 am Melco Crown Entertainment misses by $0.04, misses on revs (MPEL) :

• Reports Q3 (Sep) earnings of $0.06 per share, $0.04 worse than the Capital IQ Consensus of $0.10; revenues fell 15.9% year/year to $945.73 mln vs the $958.11 mln Capital IQ Consensus.
• Adj property EBITDA was US$237.3 mln vs US$305.7 mln yr-ago. The 22% yr/yr decline was attributable to lower contribution from the group-wide rolling chip segment and mass market table games segment.

8:09 am Ralph Lauren beats by $0.39, reports revs in-line; guides Q3 revs in-line; guides FY16 revs in-line (RL) :

• Reports Q2 (Sep) earnings of $2.13 per share, $0.39 better than the Capital IQ Consensus of $1.74; revenues fell 1.2% year/year to $1.97 bln vs the $1.95 bln Capital IQ Consensus; constant FX rev +4% vs. +3-5% guidance.
• Co issues in-line guidance for Q3, sees Q3 revs +0-2% to ~$2.03-2.07 bln vs. $2.04 bln Capital IQ Consensus Estimate.
  • Based on current exchange rates, foreign currency will have an approximate 250 basis point negative impact on revenue growth. Operating margin for the third quarter of Fiscal 2016 is expected to be ~200-250 basis points below the comparable prior year period, primarily due to negative foreign currency effects and infrastructure investments.
• Co issues in-line guidance for FY16, sees FY16 revs of flat YoY from $7.62 bln vs. $7.6 bln Capital IQ Consensus Estimate.
  • Co is maintaining its Fiscal 2016 outlook. The company expects consolidated net revenues for Fiscal 2016 to be ~flat on a reported basis and increase by 3-5% in constant currency (from mid single digit growth). Based on current exchange rates, foreign currency will have an ~400 basis point negative impact on Fiscal 2016 revenue growth. Operating margin for Fiscal 2016 is still expected to be 180-230 basis points below the prior year's level due to negative foreign currency effects. 

8:06 am LyondellBasell authorizes an interim dividend of $0.78/share (LYB) :  

8:05 am Perficient beats by $0.03, beats on revs; guides FY15 EPS in-line, revs in-line (PRFT) :

• Reports Q3 (Sep) earnings of $0.36 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.33; revenues rose 3.3% year/year to $120.9 mln vs the $118.38 mln Capital IQ Consensus.
• Co issues in-line guidance for FY15, sees EPS of $1.20-1.24 vs. $1.20 Capital IQ Consensus Estimate; sees FY15 revs of $458-468 mln vs. $461.19 mln Capital IQ Consensus Estimate.

8:04 am Sprouts Farmers Market beats by $0.02, reports revs in-line; guides FY15 EPS above consensus (SFM) :

• Reports Q3 (Sep) earnings of $0.21 per share, $0.02 better than the Capital IQ Consensus of $0.19; revenues rose 17.8% year/year to $903.1 mln vs the $897.85 mln Capital IQ Consensus.
• Reports Comparable store sales growth of 5.8% and two-year comparable store sales growth of 14.9%.
• Gross profit for the quarter increased 16% to $261.5 million, resulting in a gross profit margin of 29.0%, a decrease of 50 basis points compared to the same period in 2014. This primarily reflects the impact of continued price investments in certain categories.
• Co issues upside guidance for FY15, sees EPS of $0.83-$0.84 vs. $0.81 Capital IQ Consensus Estimate. Sees FY15 comparable store sales growth of 5-5.5% and net sales growth of 19-21%. Expects unit growth of 27 new stores. For Q4, expects comparable store sales growth of 5-6%.

8:03 am Inovio Pharma reports interim data analysis showing that INO-3112 generated specific T-cell responses and was well tolerated in patients with HPV associated head and neck cancer (INO) :

Co announced an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (:HPV) types 16 and 18.

• The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments. The characteristics of the immune response data mirror those previously observed in a phase II clinical study of VGX-3100 for HPV-associated cervical dysplasia.

8:03 am RBC Bearings beats by $0.04, misses on revs (ROLL) :

• Reports Q2 (Sep) adj earnings of $0.76 per share, $0.04 better than the Capital IQ Consensus of $0.72; revenues rose 32.1% year/year to $148.7 mln vs the $155.22 mln Capital IQ Consensus.

8:03 am Strategic Hotels & Resorts reports FFO in-line, beats on revs (BEE) :

• Reports Q3 (Sep) funds from operations of $0.25 per share, in-line with the Capital IQ Consensus of $0.25; revenues rose 16.1% year/year to $354.4 mln vs the $349.02 mln Capital IQ Consensus.
• Management has suspended the issuance of earnings guidance in light of the Company entering into a definitive merger agreement with affiliates of Blackstone Real Estate Partners VIII L.P.

8:03 am ChromaDex enters into a joint development agreement with Procter & Gamble (PG) (CDXC) : Under the terms of the agreement, ChromaDex will provide P&G exclusivity to its new proprietary ingredient for use in P&G branded products. P&G will make an undisclosed up-front payment to ChromaDex as well as other payments based on achievement of various milestones.

8:02 am Investment Tech beats by $0.18, beats on revs (ITG) :

• Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.18 better than the Capital IQ Consensus of ($0.06); revenues fell 10.7% year/year to $120.4 mln vs the $118.62 mln Capital IQ Consensus.
• There were no non-GAAP adjustments to earnings in the third quarter of 2014, however there was a net tax benefit of $2.4 million, or $0.07 per diluted share, from resolving a multi-year contingency in the U.S.
• Average daily trading volume in the U.S. of 152 million shares versus 147 million shares in the third quarter of 2014. POSIT average daily U.S. volume was 67 million shares compared to 72 million shares in the third quarter of 2014.

8:02 am Axion Power Intl completes a private placement of $9 million in senior convertible notes & warrants (AXPW) : Co has completed a private placement of $9 million principal amount of senior convertible notes and warrants with institutional investors. At closing, Axion will receive $1.60 million in proceeds, and will receive seven subsequent monthly tranches in the principal amount of $1,000,000 each and an eighth monthly tranche in the principal amount of $150,000.

8:02 am Infinity Prpty & Casualty beats by $0.35 (IPCC) :

• Reports Q3 (Sep) operating earnings of $1.41 per share, $0.35 better than the Capital IQ Consensus of $1.06; revenues rose 1.7% year/year to $372.4 mln vs the $350.4 mln two analyst estimate; book value $61.71.

8:02 am Relmada Therapeutics Responds to the 13D Filing by Laidlaw, strongly disagrees with Laidlaw's mischaracterizations and 'proposals' (RLMD) : Co stated: "While Relmada welcomes the views and input of all of its shareholders, the Board of Directors and management of the Company strongly disagree with Laidlaw's mischaracterizations and "proposals" set forth in their 13D filing. Such filing, which appears not to have been timely made, contains numerous inaccuracies and appears to disclose information about Relmada that could only have been obtained in violation of Laidlaw's responsibilities to the Company."

8:02 am Libbey beats by $0.18, misses on revs (LBY) :

• Reports Q3 (Sep) earnings of $0.75 per share, $0.18 better than the Capital IQ Consensus of $0.57; revenues fell 6.6% year/year to $201.8 mln vs the $214.81 mln Capital IQ Consensus.
• "Our core foodservice channel continues to be very strong around the globe in the face of declining restaurant traffic trends. This is the sixth consecutive quarter of growth in foodservice for the Company. Unfortunately, that was offset in the third quarter by weakness in our retail and business-to-business channels."

8:02 am Kona Grill announces authorization for a $10 mln share repurchase plan (KONA) : The current authorization replaces the Co's 2012 $5 mln repurchase plan under which $1.8 mln remained available for repurchase.

8:01 am Microvision reports EPS in-line, misses on revs (MVIS) :

• Reports Q3 (Sep) loss of $0.07 per share, in-line with the two analyst estimate of ($0.07); revenues rose 146.4% year/year to $2.39 mln vs the $4 mln single analyst estimate.

8:01 am CACI Intl receives $38.5 mln task order to continue providing defense health readiness engineering support for the Theater Medical Information Program (CACI) : Co has been awarded a $38.5 million task order to continue providing defense health readiness engineering support for the Theater Medical Information Program for the Space and Naval Warfare Systems Center Atlantic.

8:01 am AEP Industries appoints John Powers as Chief Operating Officer and President, effective immediately (AEPI) : Co announced John J. Powers, EVP of Sales and Marketing and a member of the Board of Directors, has been appointed to the newly created position of Chief Operating Officer and has assumed the role of President, effective immediately

8:00 am Chimerix reports Q3 results; Topline Data from SUPPRESS Trial of Brincidofovir anticipated in early 2016 (CMRX) :

• Q3 EPS ($0.70) vs ($0.57) Capital IQ Consensus; revs +92% to $2.3 mln vs $2.20 mln Capital IQ Consensus.
• Topline Data from SUPPRESS Trial of Brincidofovir for Prevention of Cytomegalovirus in Hematopoietic Cell Transplant Recipients Anticipated in Early 2016
• Dosing Initiated in Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients

8:00 am On the Wires (:WIRES) :

• UQM Technologies (UQM) announced the receipt of a new purchase order from Proterra for the UQM PowerPhase 220 HD motor and controller systems with deliveries starting in early January 2016. The units will be used in the Proterra Catalyst Bus program
• Cask Data announced that it is raising a $20 million Series B financing round led by Safeguard Scientifics (SFE) with participation from Battery Ventures, Ignition Partners and other existing investors

7:59 am RAIT Financial Trust reports Q3 Cash Available for Distribution per share of $0.27, vs. $0.00 for 3Q14 (RAS) :  

7:58 am Braskem SA reports Q3 results (BAK) : Co reports Q3 (Sep) net income of R$1,482 million, reflecting the good operating performance and the adoption of hedge accounting. Resin exports totaled to 454 kton, 22% and 43% up on 2Q15 and 3Q14, respectively. Exports of key basic petrochemicals reached 482 kton, up 35% and 19% from 2Q15 and 3Q14, respectively. The international unit posted record-high PP sales volume of 502 kton, representing growth of 2% on 2Q15, driven by a strong operating performance and recovery of the US economy. The construction of the petrochemical complex in Mexico reached 98% of completion, with progress made on the pre-commissioning activities.

7:57 am Antares Pharma reports Q3 results (ATRS) :

• Q3 ($0.04) vs ($0.04) Capital IQ Consensus Estimate; revs $11.1 mln vs $9.93 mln Capital IQ Consensus.
• "We believe the third quarter operating and financial results speak to the progress we are making against three of our top-priority goals, including continuing to grow Otrexup, delivering epinephrine devices to Teva and progressing the QuickShot Testosterone clinical program."

7:56 am S&P futures vs fair value: +7.80. Nasdaq futures vs fair value: +15.30. (:WRAPX) :

U.S. equity futures trade near their pre-market highs amid upbeat action overseas. The S&P 500 futures hover eight points above fair value after hitting pre-market highs during the past 30 minutes.

On the economic front, weekly Initial Claims (Briefing.com consensus 262,000) and preliminary Q3 Productivity/Unit Labor Cost data will be reported at 8:30 ET.

Treasuries sit just below their flat lines with the 10-yr yield at 2.23%.

In U.S. corporate news of note:

• Facebook (FB 108.60, +4.66): +4.5% in reaction to better than expected results.
• Qualcomm (QCOM 56.27, -3.99): -6.6% after below-consensus guidance overshadowed better than expected results.
• Whole Foods (WFM 28.75, -2.01): -6.5% after below-consensus earnings and cautious guidance overshadowed a $1 billion increase in the company's buyback and a 4.0% quarterly dividend hike to $0.135/share.
• AstraZeneca (AZN 33.01, +0.88): +2.7% after beating bottom-line estimates and guiding ahead of analyst expectations.
• Celgene (CELG 122.49, -4.68): -3.7% after reporting a one-cent beat on below-consensus revenue.
• Select Comfort (SCSS 23.75, +2.31): +10.8% after beating estimates and reaffirming its guidance.

Reviewing overnight developments:

• Asian markets ended mixed. Japan's Nikkei +1.0%, China's Shanghai Composite +1.8%, and Hong Kong's Hang Seng settled flat
  • In economic data:
    • Indonesia's Q3 GDP +3.2% (expected 3.3%)
    • Taiwan's October CPI +0.3% (expected 0.2%)
  • In news:
    • The Bank of Japan released the minutes from its latest meeting, but there was no change in the tone among policymakers as they continue expecting an uptick in inflation

• Major European indices trade higher across the board. France's CAC +1.2%, Germany's DAX +1.0%, and UK's FTSE +0.1%. Elsewhere, Italy's MIB +0.5% and Spain's IBEX +0.7%
  • Investors received several data points:
    • Eurozone September Retail Sales -0.1% month-over-month (expected 0.2%; prior 0.0%); +2.9% year-over-year (consensus 3.0%; prior 2.2%). Separately, Retail PMI 51.3 (prior 51.9)
    • Germany's September Factory Orders -1.7% month-over-month (expected 1.0%; previous -1.8%)
    • UK's October Halifax House Price Index +1.1% month-over-month (consensus 0.6%; prior -0.9%); +9.7% year-over-year (consensus 9.5%; last 8.6%)
    • Swiss October CPI +0.1% month-over-month (expected 0.0%; prior 0.1%); -1.4% year-over-year, as expected (prior -1.4%). Separately, Q4 SECO Consumer Climate -18 (expected -14; previous -19)
  • Among news of note:
    • The Bank of England made no changes to its policy stance, keeping its interest rate and purchase program unchanged at their respective 0.50% and GBP375 billion. Furthermore, the central bank's policy minutes revealed no change in attitude among participants with eight members calling for no change to policy while one member remained in the rate hike camp.

7:54 am Alliqua beats by $0.05, misses on revs; lowers FY15 revenue guidance (ALQA) :

• Reports Q3 (Sep) non-GAAP loss of $(0.18) per share, $0.05 better than the Capital IQ Consensus of $(0.23); revenues rose 236% year/year to $5.0 mln vs the $5.54 mln Capital IQ Consensus.
• Co guides to FY15 revenue of $15-16 mln, down from prior guidance of $16.3-18.8 mln and vs consensus of $17.6 mln. The decrease in guidance is primarily driven by lower than expected sales of Biovance, offset partially by higher than expected sales of MIST Therapy and contract manufacturing revenue.

7:54 am Easterly Government Properties reports FFO in-line, beats on revs; guides FY15 FFO above consensus; guides FY16 FFO above consensus (DEA) :

• Reports Q3 (Sep) funds from operations of $0.26 per share, in-line with the Capital IQ Consensus of $0.26; revs $19.85 mln vs $18.76 mln consensus.
• Co issues upside guidance for FY15, sees FFO of $1.01-1.05 vs. $1.00 Capital IQ Consensus Estimate.
• Co issues upside guidance for FY16, sees FFO of $1.14-1.18 vs. $1.10 Capital IQ Consensus Estimate.

7:54 am Nuverra Environmental Solutions misses by $0.24, misses on revs (NES) :

• Reports Q3 (Sep) adj. loss of $0.81 per share, $0.24 worse than the Capital IQ Consensus of ($0.57); revenues fell 45.2% year/year to $76.5 mln vs the $90.15 mln Capital IQ Consensus. 
• "The third quarter saw volume and pricing headwinds as customers reduced drilling and completion activities. To position the company to weather these trends, which we expect to continue into 2016, we continued to focus on our cost-management and efficiency initiatives with a goal of operating within our cash flow as we work to complete the next steps to transform our business."

7:53 am Genocea Biosciences reports Q3 (GNCA) : Reports Q3 (Sep) loss of ($0.37) per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of a loss of ($0.44); revenues rose year/year to $0.233 mln vs the $0.07 mln Capital IQ Consensus.

7:48 am EndoChoice beats by $0.04, reports revs in-line; guides FY15 EPS below consensus, revs below consensus (GI) :

• Reports Q3 (Sep) loss of $0.47 per share, $0.04 better than the Capital IQ Consensus of ($0.51); revenues rose 29.9% year/year to $18.4 mln vs the $18.23 mln Capital IQ Consensus.
• Co issues downside guidance for FY15, sees EPS of ($2.90)-($2.85) vs. ($2.83) Capital IQ Consensus Estimate; sees FY15 revs of $72-74 mln vs. $74.51 mln Capital IQ Consensus Estimate.

7:47 am Toyota Motor reports 1H16 results; revenue increased 8.9% YoY (TM) : Co reports FY16 first half results. Revenue increased 8.9% YoY to 14,091.4 billion yen in FY2016 first half. Operating income increased by 17.1% YoY to 1,583.4 billion yen in FY2016 first half. Net income increased 11.6% YoY to 1,258.1 billion yen in FY2016 first half. Consolidated vehicle unit sales in Japan and overseas decreased by 4.4% YoY to 4,278 thousand units in FY2016 first half. Vehicle unit sales in Japan decreased by 4.4% to 984 thousand units while overseas vehicle unit sales decreased by 4.4%, to 3,294 thousand units in FY2016 first half.

7:43 am Agrium beats by $0.04, misses on revs; guides FY15 EPS midpoint above consensus (AGU) :

• Reports Q3 (Sep) earnings of $0.71 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.67; revenues fell 13.6% year/year to $2.52 bln vs the $2.87 bln Capital IQ Consensus.
• Co issues upside guidance for FY15, sees EPS of $7.10-7.40 vs. $7.10 Capital IQ Consensus Estimate.

7:43 am Repligen beats by $0.01, beats on revs; guides FY15 revs above consensus, raises low end of net income guidance (RGEN) :

• Reports Q3 (Sep) earnings of $0.08 per share, $0.01 better than the Capital IQ Consensus of $0.07; revenues rose 29.4% year/year to $19.8 mln vs the $19.19 mln Capital IQ Consensus.
• Product gross profit for the third quarter of 2015 was $11.4 ml compared to product gross profit of $8.2 mln for the third quarter of 2014, an increase of 38%.
• Co issues upside guidance for FY15, sees FY15 revs of $81-$83 mln vs. $80.20 mln Capital IQ Consensus Estimate. Its revenue projection for 2015 is comprised exclusively of bioprocessing product sales and reflects growth in the range of 34%-37%, an increase from previous guidance of 29%-36%. It expects the additional five months of ATF System sales in 2015 versus 2014 to effectively offset the impact of foreign currency translation, which we estimate will be negative 9%.
  
  Co expects product gross margin for the year 2015 is expected to be 57%-59%, an increase from our previous guidance of 56%-58%. Total income from operations for the year 2015 is expected to be $15-$16 mln, an adjustment to its previous guidance of $14-$16 million. Net income is expected to be $11-$12 million, an adjustment to previous guidance of $10-$12 million.
  

7:42 am Lexington beats by $0.01, reports revs in-line; raises FY15 FFO guidance but remains below consensus; announces 10 mln share buyback (LXP) :

• Reports Q3 (Sep) funds from operations of $0.27 per share, $0.01 better than the Capital IQ Consensus of $0.26; revenues fell 1.1% year/year to $105.43 mln vs the $105.85 mln Capital IQ Consensus.
• Co issues downside guidance for FY15, sees FFO of $1.05-1.07 vs. $1.08 Capital IQ Consensus Estimate, $1.02-1.06
• Co announced a 10 mln common share repurchase authorization and repurchased 1.6 million common shares, at an average price of $8.34 per share.

7:41 am Spartan Motors misses by $0.07, misses on revs (SPAR) :

• Reports Q3 (Sep) net of breakeven, excluding non-recurring items, $0.07 worse than the two analyst estimate of $0.07; revenues fell 5.3% year/year to $136.6 mln vs the $150.1 mln two analyst estimate. Order backlog increased to $275.3 million at September 30, 2015, from $233.4 million at September 30, 2014

7:41 am CECO Environ. beats by $0.05, beats on revs (CECE) :

• Reports Q3 (Sep) earnings of $0.27 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.22; revenues rose 55.2% year/year to $98.23 mln vs the $94.61 mln Capital IQ Consensus.
• Non-GAAP operating margin improved to 13.2% from 12.9% n the prior-year period.

7:41 am Overnight Treasury Summary (BOND) :

Treasuries Flatline Overnight

• Treasuries are generally unchanged this morning and the yield curve is just a touch steeper ahead of the release of weekly jobless claims and unit labor costs for the third quarter of 2015. There are several FOMC members speaking publicly today, although many are simply giving introductory remarks or participating in panels that have nothing to do with the macroeconomic outlook or near-term direction of monetary policy. Positioning should be tentative ahead of Friday's release of the October Employment Situation Report. S&P 500 futures are pointing to a higher open, up 0.34% to 2,109.4
  
• Yield Check:
  
  • 2-yr: -1 bp to 0.83%
    
  • 5-yr: unch at 1.63%
    
  • 10-yr: +1 bp to 2.23%
    
  • 30-yr: +1 bp to 3.01%

• International News:
  
  • The Bank of England voted 8-1 in favor of holding its main policy rate at 0.5%
    
    • The central bank also forecast that consumer prices would grow at less than 1% until H2 2016 in its quarterly inflation report, while also citing downside risks to the outlook
      
    • The 2015 and 2016 GDP growth forecasts were both lowered to 2.7% and 2.5%, respectively
      
    • The BoE saw the domestic economic picture as strong, helped along by low energy prices and interest rates, while the risk factors were mostly external
      
  • The U.K.'s Halifax House Price Index rose a better-than-expected 1.1% m/m in October after falling 0.9% in September. The index was up 9.7% y/y
    
  • Eurozone retail sales fell 0.1% m/m in September, confounding economists' expectations for a modest gain. Retail sales were unchanged in August
    
    • In Germany, factory orders unexpectedly fell 1.7% m/m in September after declining 1.8% in August
      
  • Russia's services purchasing managers' index, as compiled by Markit, fell more than expected to 47.8 in October from 51.3 in September
    
    • The Bank of Russia's reserves fell to $369.2 bln from $374.6 bln
      
  • Japan's Ministry of Finance auctioned JPY 2.4 tln ($19.76 bln) of 10-year JGBs at a high yield of 0.320%. The auction tailed ever so slightly and drew a bid-to-cover ratio of 2.80

• Data out Today:
  
  • October Challenger Job Cuts (07:30 ET)
    
  • Initial Jobless Claims for the week ending 10/31 and Continuing Jobless Claims for the week ending 10/24 (08:30 ET)
    
  • Q3 Productivity and Unit Labor Costs -- Preliminary (08:30 ET)
  • Natural Gas Inventories for the week ending 10/31 (10:30 ET)
    
• Fed Speakers:
  
  • Philadelphia Fed President Harker (non-FOMC voter) -- introductory remarks (08:30 ET)
    
  • New York Fed President Dudley (FOMC voter) -- introductory remarks (08:30 ET)
    
  • Fed Vice Chair Fischer (FOMC voter) -- participates in discussion (09:10 ET)
    
  • Chicago Fed President Evans (FOMC voter) -- introductory remarks (10:40 ET)
    
  • Fed Governor Tarullo (FOMC voter) -- "Sharing Responsibility for the Regulation of International Banks" (13:25 ET)
    
  • Atlanta Fed President Lockhart (FOMC voter) (14:30 ET)
    
  • Former Fed Chair Bernanke -- gives lecture at "Unconventional Monetary and Exchange Rate Policies" Conference (16:00 ET)

7:41 am Celgene beats by $0.01, misses on revs; reaffirms FY15 guidance; raises REVLIMID guidance, lowers ABRAXNE (CELG) :

• Reports Q3 (Sep) earnings of $1.23 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.22; revenues rose 17.8% year/year to $2.33 bln vs the $2.4 bln Capital IQ Consensus. 
  • REVLIMID sales for the third quarter increased 12 percent to $1,453 million. U.S. sales of $895 million and International sales of $558 million increased 18 percent and 3 percent year-over-year, respectively. Volume was the main driver of the increase as both market share and duration trends are positive across major geographies.
• Co reaffirms guidance for FY15, sees EPS of $4.75-4.85, excluding non-recurring items, vs. $4.82 Capital IQ Consensus Estimate; sees FY15 revs of $9.0-9.5 bln vs. $9.28 bln Capital IQ Consensus Estimate. 
  • REVLIMID net sales are expected to be ~$5.8 billion, an increase from the previous range of $5.6 billion to $5.7 billion
  • ABRAXANE net sales are expected to be in the range of $950 million to $1.0 billion, a decrease from the previous range of $1.0 billion to $1.25 billion
• Adjusted 2015 operating margin remains unchanged at ~52%.  
• Over 150 abstracts expected at medical congresses in Q4, including many at ASH

7:40 am Media General reports Q3 (Sep) results, revs in-line; guides Q4 revs in-line (MEG) :

• Reports Q3 (Sep) loss of $0.38 per share, may not be comparable to the two analyst estimate of $0.03; revenues rose 101.3% year/year to $322 mln vs the $323.13 mln Capital IQ Consensus.
• Co issues in-line guidance for Q4, sees Q4 revs of $366-377 mln vs. $375.16 mln Capital IQ Consensus Estimate.

7:39 am Chemours beats by $0.14, reports revs in-line (CC) :

• Reports Q3 (Sep) earnings of $0.40 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus of $0.26; revenues fell 8.9% year/year to $1.49 bln vs the $1.5 bln Capital IQ Consensus.
  • In the third quarter, Titanium Technologies segment sales were $616 mln, an 18% decline versus the prior-year quarter.
  • Fluoroproducts segment sales in the third quarter were $575 mln, flat versus the prior-year quarter
  • In the third quarter, Chemical Solutions segment sales were $295 mln, a 4% decline versus the prior-year quarter
  • In the third quarter, Chemical Solutions segment sales were $295 mln, a 4% decline versus the prior-year quarter.

7:38 am Enviva Partners misses by $0.01, beats on revs (EVA) :

• Reports Q3 (Sep) earnings of $0.27 per share, $0.01 worse than the Capital IQ Consensus of $0.28; revenues rose 53.2% year/year to $116.6 mln vs the $104.49 mln single analyst estimate.
• "Consistent with previous guidance, the Partnership expects its existing business to generate net income in the range of $5.6 million to $6.6 million and adjusted EBITDA in the range of $14.8 million to $15.8 million, and to incur maintenance capital expenditures in the range of $0.5 million to $1.0 million and interest expense net of amortization of debt issuance costs and original issue discount of $2.5 million in the fourth quarter of 2015. As a result, the Partnership expects to generate distributable cash flow of $11.3 million to $12.3 million during the fourth quarter of 2015."

7:37 am Atlas Air Worldwide reports EPS in-line, misses on revs; guides Q4 EPS above consensus (AAWW) :

• Reports Q3 (Sep) earnings of $1.23 per share, in-line with the Capital IQ Consensus of $1.23; revenues fell 3.4% year/year to $449.9 mln vs the $472.74 mln Capital IQ Consensus.
• Co issues upside guidance for Q4, sees EPS of slightly more than $1.50 vs. $1.50 Capital IQ Consensus Estimate.

7:37 am Apollo Investment reports EPS in-line, revs in-line (AINV) :

• Reports Q2 (Sep) earnings of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; Total investment income fell 17.2% year/year to $98.42 mln vs the $98.89 mln Capital IQ Consensus.

7:37 am Martha Stewart misses by $0.07, misses on revs (MSO) :

• Reports Q3 (Sep) loss of $0.03 per share, $0.07 worse than the two analyst estimate of $0.04; revenues fell 41.2% year/year to $17.4 mln vs the $20.9 mln two analyst estimate.

7:37 am Blue Nile beats by $0.01, reports revs in-line; guides Q4 EPS in-line, revs in-line; authorizes $100 mln renewed share repurchase program (NILE) :

• Reports Q3 (Sep) earnings of $0.17 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.16; revenues rose 3.9% year/year to $109.9 mln vs the $110.83 mln Capital IQ Consensus.  Earnings per diluted share included stock-based compensation expense of $0.07 for the third quarter 2015 and $0.05 for the third quarter 2014.
  
• Co issues in-line guidance for Q4, sees EPS of $0.41-0.47, excluding non-recurring items, vs. $0.44 Capital IQ Consensus Estimate; sees Q4 revs of $158-168 mln vs. $163.98 mln Capital IQ Consensus Estimate. 
• Blue Nile's Board of Directors authorized the renewal of the Company's share repurchase program. The Company is authorized to repurchase up to $100.0 million of its common stock over the next 27 months.

7:36 am TECO Energy beats by $0.02, reports revs in-line (TE) :

• Reports Q3 (Sep) earnings of $0.33 per share, $0.02 better than the Capital IQ Consensus of $0.31; revenues rose 1.0% year/year to $693.8 mln vs the $698.88 mln Capital IQ Consensus. 
• On Sept. 4, we announced that Emera, Inc. would acquire TECO Energy for $27.55 per share. On Sept. 21, we closed the sale of TECO Coal, our last unregulated business, thus completing our transformation to a regulated utility business.

7:36 am Gogo beats by $0.04, beats on revs; reaffirms FY15 revs guidance; raises EBITDA (GOGO) :

• Reports Q3 (Sep) loss of $0.37 per share, $0.04 better than the Capital IQ Consensus of ($0.41); revenues rose 21.5% year/year to $126.4 mln vs the $123.71 mln Capital IQ Consensus. Service revenue increased to $107.2 million, up 31% from $81.6 million in Q3 2014.
  • Adjusted EBITDA increased to $9.7 million, up 738% or $8.5 million from $1.2 million in Q3 2014.
• Co reaffirms guidance for FY15, sees FY15 revs of $485-505 mln vs. $491.51 mln Capital IQ Consensus; raises FY15 EBITDA to $30-35 mln from $15-25 mln.
• "We are extremely pleased with our strong financial performance for the quarter, and even more pleased with the flight test results of 2Ku, our next generation global connectivity solution, and that portends great things for our future."

7:35 am Primoris Services reports EPS in-line, misses on revs (PRIM) :

• Reports Q3 (Sep) earnings of $0.37 per share, in-line with the Capital IQ Consensus of $0.37; revenues fell 9.3% year/year to $555.9 mln vs the $601.49 mln Capital IQ Consensus.
  • Third quarter 2015 revenues were impacted by the delay in certain capital projects as a result of lower oil prices and as a result of close-outs of large projects in the prior year

7:34 am Calgon Carbon misses by $0.02, misses on revs (CCC) :

• Reports Q3 (Sep) earnings of $0.23 per share, $0.02 worse than the Capital IQ Consensus of $0.25; revenues fell 3.4% year/year to $133 mln vs the $141.3 mln Capital IQ Consensus.

7:34 am Houston Wire & Cable misses by $0.02, beats on revs (HWCC) :

• Reports Q3 (Sep) earnings of $0.06 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of $0.08; revenues fell 19.0% year/year to $78.3 mln vs the $73.98 mln Capital IQ Consensus.
• Gross margin at 20.6% decreased 120 basis points from the third quarter of 2014 primarily due to lower product margins and vendor rebates, partially offset by lower customer incentives.
• Debt decreased to $38.8 million, the lowest level since Q1 2010

7:32 am Aeropostale receives a notice of non-compliance from the NYSE for failing to meet the exchange's minimum market cap standard; co plans to submit a plan to cure the deficiency (ARO) :  

7:32 am Meridian Bioscience misses by $0.01, beats on revs; guides FY15 EPS in-line, revs in-line (VIVO) :

• Reports Q4 (Sep) earnings of $0.20 per share, $0.01 worse than the Capital IQ Consensus of $0.21; revenues rose 0.9% year/year to $47.1 mln vs the $45.7 mln Capital IQ Consensus.
• Co issues in-line guidance for FY15, sees EPS of $0.86-0.90 vs. $0.86 Capital IQ Consensus Estimate; sees FY15 revs of $195-200 mln vs. $193.50 mln Capital IQ Consensus Estimate.

7:32 am Crocs appoints Carrie Teffner as CFO, effective December 16, 2015 (CROX) : Prior to joining Crocs' board of directors, Teffner served as EVP and CFO for PetSmart

7:31 am Core-Mark misses by $0.08, reports revs in-line; revises FY15 EPS guidance, reaffirms FY15 revs guidance; raises dividend (CORE) :

• Reports Q3 (Sep) GAAP earnings of $0.65 per share, $0.08 worse than the Capital IQ GAAP Consensus of $0.73; revenues rose 8.9% year/year to $2.99 bln vs the $2.97 bln Capital IQ Consensus.
• Co revises EPS guidance for FY15, sees GAAP EPS of $2.08-2.15 (prior $2.03-2.10) vs. $2.12 Capital IQ Consensus Estimate; reaffirms FY15 revs guidance of $11-11.2 bln vs. $11.07 bln Capital IQ Consensus Estimate.
• Core-Mark also announced its Board of Directors has approved a $0.16 cash dividend per common share for the fourth quarter, or $0.64 annually, an increase of $0.03 per quarter from the prior dividend.

7:30 am Realogy misses by $0.05, beats on revs (RLGY) :

• Reports Q3 (Sep) earnings of $0.76 per share, excluding non-recurring items, $0.05 worse than the Capital IQ Consensus of $0.81; revenues rose 8.9% year/year to $1.67 bln vs the $1.65 bln Capital IQ Consensus. 
• Co is raising its outlook for Adjusted EBITDA to a range of $830 million to $845 million, up from its previously provided range of $810 million to $840 million. The Company is also raising its Adjusted EBITDA margin outlook for the full year 2015 to a range of 14.4% to 14.6%, up from its previously provided range of 14.1% to 14.3%.

7:29 am On the Wires (:WIRES) :

• CareFusion, a BD company (BDX) announced its AirLife business line has signed an exclusive agreement with ResMed (RMD) to distribute nasal high flow interface products from the company
• Siliconware Precision Industries (SPIL) Board of Directors resolved to invest in 100% owned subsidiary, Siliconware Investment Co, for NTD 2.401 billion and acquire 48,020,000 common shares- and for Siliconware Investment to invest in Yann Yuan Investment for NTD 2.4 billion and acquire 48,000,000 common shares.
• KVH Industries' (KVHI) guidance and stabilization business awarded two contracts totaling $2.7 mln: a $1.3 mln contract to provide field service representative support to an allied country in the Middle East related to Co's tactical navigation systems; and, a $1.4 mln contract for the delivery of TACNAV systems for use by an international military customer
• xG Technology (XGTI) announced an order for ~$200K from the US State Dpmt for xMax mobile broadband wireless netowrking equipment and associated support services.
• Skyline Medical (SKLN) initiated 12 new trials of the STREAMWAY System in 8 different states across the U.S.
  

7:29 am Dawson Geophys beats Q3 estimates; demand to remain soft in FY16 (DWSN) :

• Q3 ($0.13) vs ($0.42) two analyst estimate; revs $62.5 mln vs $55.94 mln two analyst estimate
• "The Company operated approximately ten crews in the United States with limited activity in Canada during the third quarter of 2015. Improved weather conditions, operational discipline, and strong financial management, in the Company's areas of operations lead to increased crew utilization in the third quarter of 2015 as compared to the second quarter of 2015, and resulted in a 108% increase in EBITDA from the same period in 2014. Despite the year-over-year improvement in EBITDA, demand for services is at reduced levels from recent years and is anticipated to remain so into 2016 in response to decreased and uncertain commodity prices and reduced client expenditures. The Company anticipates operating eight to ten crews in the United States with limited activity in Canada during the fourth quarter ending December 31, 2015 and into the latter part of the first quarter of 2016."

7:29 am On the Wires (:WIRES) :

• Affymetrix (AFFX) and XRGenomics announced that they will collaborate on research and development of a new generation of diagnostic tests for age-related diseases. XRGenomics has utilized Affymetrix technology to develop novel gene expression-based signatures that enable translational research and biomarker test development activities in areas such as dementia, Alzheimer's, and other age-related diseases.
• Isis Pharmaceuticals (ISIS) announced the start of a Phase 3 study to evaluate the efficacy and safety of volanesorsen in patients with familial partial lipodystrophy. The study's primary objective will be to evaluate the efficacy and safety of a 300 mg once weekly dose of volanesorsen given over 12 months. The primary endpoint of the study is percent change in fasting triglycerides from baseline after three months of dosing.
• Genocea Biosciences (GNCA) announced a collaboration with Memorial Sloan Kettering Cancer Center to screen the T cell responses of melanoma and non-small cell lung cancer patients treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. The goals of the collaboration are to identify signatures of T cell response in cancer patients associated with response or non-response to CPI therapy and to discover new T cell cancer vaccine antigens.
• Biocept (BIOC) announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood based biopsy, instead of surgical biopsy

7:25 am Pattern Energy reports Q3; raises dividend 2.5% QoQ (PEGI) :

• Reports Q3 (Sep) GAAP loss of $0.40 per share, may not compare to the Capital IQ Consensus of ($0.12); revenues rose 25.5% year/year to $89.7 mln vs the $87.97 mln Capital IQ Consensus.
  • The changes in net loss are primarily due to third quarter other expense items associated with Gulf Wind's early extinguishment of debt and termination of associated interest rate instruments. In addition, the net loss for the third quarter increased due to unrealized losses on interest rate derivatives, and losses in unconsolidated investments as a result of decreasing forward interest rate curves.
• Cash available for distribution (CAFD) of $22.3 mln, up 104%
• Adjusted EBITDA of $58.7 million, up 32%
• Proportional GWh sold of 1,256 GWh, up 77%
• Re-iterated 2015 cash available for distribution estimate of $81 million to $87 million
• Raises dividend 2.5% QoQ to $0.372

7:24 am Charter Comm subsidiary to offer $2.5 bln in aggregate principal amount of senior unsecured notes due 2026 (CHTR) :

Co announces that its subsidiary, CCOH Safari, LLC, intends to offer $2.5 bln in aggregate principal amount of senior unsecured notes due 2026.

• Co Charter intends to use the net proceeds from the sale of the Notes to partially finance Co's previously announced transactions with Time Warner Cable Inc. (TWC) and Bright House Networks, LLC.
• The Notes will be assumed by Co's subsidiaries, CCO Holdings, LLC and CCO Holdings Capital Corp.

7:22 am TreeHouse Foods beats by $0.03, misses on revs (in-line with Monday's preannouncement); reaffirms FY15 EPS guidance (THS) :

• Reports Q3 (Sep) earnings of $0.86 per share, $0.03 better than the Capital IQ Consensus of $0.83; revenues rose 0.4% year/year to $798.64 mln vs the $822.37 mln Capital IQ Consensus.
• Co reaffirms guidance for FY15, sees EPS of $3.00-3.15 vs. $3.07 Capital IQ Consensus Estimate.
• Adjusted earnings before interest, taxes, depreciation, amortization, and non-cash stock based compensation, or Adjusted EBITDA, was $99.8 million in the third quarter of 2015, a 3.6% decrease compared to the prior year. Adjusted EBITDA was lower this quarter due to competitive pressures in most categories and unfavorable foreign exchange.

7:19 am Chesapeake Utilities beats by $0.07, misses on revs (CPK) :

• Reports Q3 (Sep) earnings of $0.33 per share, $0.07 better than the Capital IQ Consensus of $0.26; revenues rose 0.3% year/year to $91.91 mln vs the $96.01 mln two analyst estimate.

7:19 am McEwen Mining reports Q3 operating and financial results (MUX) : Co reports Q3 adjusted EPS of $0.00 vs $0.03 in the prior year period. Co also reports record quarterly production of 43,390 gold equivalent ounces and earnings from mining operations of $13.4 mln for Q3. The El Gallo Mine in Mexico was the star performer in the quarter, producing at total cash costs and all-in sustaining costs (AISCF) per gold equivalent ounce of $454 and $570, respectively.

7:18 am Duke Energy misses by $0.04, misses on revs; sees FY15 EPS at low half of prior range (DUK) :

• Reports Q3 (Sep) earnings of $1.47 per share, $0.04 worse than the Capital IQ Consensus of $1.51; revenues rose 1.4% year/year to $6.48 bln vs the $6.77 bln Capital IQ Consensus.
  • Earnings for the third quarter of 2015 were higher than the prior year quarterly results, primarily due to warmer weather compared to the previous year. The company also experienced strong growth in the Regulated Utilities business, including the impact of the recently completed North Carolina Eastern Municipal Power Agency (:NCEMPA) acquisition.
  • During 2015, the co has been able to offset weakness in the International business with favorable weather, solid operational performance in the regulated business, and benefits from closing certain strategic initiatives earlier than anticipated
• Co issues in-line guidance for FY15, sees EPS of $4.55-4.65 from $4.55-4.75 vs. $4.63 Capital IQ Consensus Estimate. 

7:18 am Huntington Ingalls misses by $0.03, beats on revs (HII) :

• Reports Q3 (Sep) earnings of $1.98 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of $2.01; revenues rose 4.8% year/year to $1.8 bln vs the $1.71 bln Capital IQ Consensus. 
• New contract awards were ~$0.8 billion for the quarter, bringing total backlog at the end of Q3 2015 to $23.3 billion, of which $12.5 billion was funded.

7:15 am Cogent Communications beats by $0.01, beats on revs (CCOI) :

• Reports Q3 (Sep) earnings of $0.07 per share, $0.01 better than the Capital IQ Consensus of $0.06; revenues rose 7.6% year/year to $103.01 mln vs the $100.83 mln Capital IQ Consensus.

7:15 am Coty beats by $0.29, misses on revs (COTY) :

• Reports Q1 (Sep) earnings of $0.59 per share, excluding non-recurring items, $0.29 better than the Capital IQ Consensus of $0.30; non-GAAP revenues fell 5.9% year/year to $1.11 bln vs the $1.14 bln Capital IQ Consensus.
• Note: In July 2015, COTY announced it will merge with the Procter & Gamble's (PG) Specialty Beauty Business. Since that time much has happened. Over the last few months, the financing structure for this transaction has been put in place. Extensive discussions with the twelve licensors have taken place with respect to the transfer of their fragrance licenses to Coty. To date, ten out of the twelve licenses will transfer to Coty upon regulatory approval and completion of the transaction. Co says this has allowed it to stay on track with the regulatory clearance process. As a result, co continues to anticipate the deal will close in the second half of calendar 2016.

7:15 am EnerNOC misses by $0.16, misses on revs; guides Q4 EPS in-line, revs below consensus (ENOC) :

• Reports Q3 (Sep) earnings of $0.74 per share, excluding non-recurring items, $0.16 worse than the Capital IQ Consensus of $0.90; revenues fell 34.0% year/year to $217.3 mln vs the $232.18 mln Capital IQ Consensus.
• Co issues guidance for Q4, sees EPS of ($1.13) - ($0.97) vs. ($0.99) Capital IQ Consensus Estimate; sees Q4 revs of $50-60 mln vs. $65.90 mln Capital IQ Consensus Estimate. 
• Co signed a multi-year software contract with UK energy retailer SmartestEnergy. SmartestEnergy will leverage the Company's software to launch new products for its business customers.

7:14 am Rice Energy beats by $0.03, misses on revs (RICE) :

• Reports Q3 (Sep) earnings of $0.03 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of ($0.00); revenues rose 81.5% year/year to $143.6 mln vs the $157.53 mln Capital IQ Consensus.
• Effective Oct 30, 2015, the borrowing base under its upstream credit facility was increased by $100 mln to $750 mln, representing a 15% increase.
• On Nov 4, 2015, Rice Midstream Holdings received $200 mln from RMP as consideration for the water services business acquisition.
• As of Sept 30, 2015, its liquidity position pro forma for its borrowing base redetermination, water services business drop down and excluding RMP and the potential earn out, was $1.2 bln, consisting of $625 mln available under its upstream credit facility, $300 mln available under its retained midstream credit facility and $240 mln of cash on hand.
• Co had 66% of its Q3 production hedged at an average Henry Hub floor price of $4.02 per MMBtu. For Q4, co has 503 BBtu/d of its expected production hedged at a weighted average fixed floor price of $3.78/MMBtu. In addition, co currently has hedged an average of 489 and 375 BBtu/d in 2016 and 2017, respectively, at a weighted average floor price of $3.51 and $3.34/MMBtu.

7:14 am ANSYS beats by $0.03, reports revs in-line; guides Q4 EPS below consensus, revs below consensus; guides FY16 EPS below consensus, revs in-line (ANSS) :

• Reports Q3 (Sep) earnings of $0.90 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.87; revenues rose 1.1% year/year to $238.2 mln vs the $238.42 mln Capital IQ Consensus. Recurring revenue, which is comprised of lease license and annual maintenance revenue, totaled 72% of revenue for the third quarter.
• Co issues downside guidance for Q4, sees EPS of $0.83-0.88, excluding non-recurring items, vs. $0.94 Capital IQ Consensus Estimate; sees Q4 revs of $252-260 mln, excluding non-recurring items, vs. $266.15 mln Capital IQ Consensus Estimate.
• Co issues guidance for FY16, sees EPS of $3.58-3.76, excluding non-recurring items, vs. $3.79 Capital IQ Consensus Estimate; sees FY16 revs of $1.01-1.05 bln, excluding non-recurring items, vs. $1.04 bln Capital IQ Consensus Estimate.

7:14 am Radius Health misses by $0.10; on track to submit MAA in the EU and NDA in the U.S. for abaloparatide-SC by the end of this year (RDUS) :

• Reports Q3 (Sep) loss of $0.68 per share, $0.10 worse than the Capital IQ Consensus of ($0.58). 
• "Radius was pleased to have the opportunity to present the positive results of our Phase III ACTIVE and ACTIVExtend trials for our investigational drug abaloparatide-SC for the treatment of postmenopausal osteoporosis at the American Society for Bone and Mineral Research, and we are on track to submit our MAA in the EU and NDA in the U.S. by the end of this year."

7:14 am BCE Inc beats by $0.08, reports revs in-line; reaffirms FY15 guidance (BCE) :

• Reports Q3 (Sep) earnings of CC$0.93 per share, CC$0.08 better than the Capital IQ Consensus of CC$0.85; revenues rose 2.9% year/year to CC$5.34 bln vs the CC$5.3 bln Capital IQ Consensus.
  • Reports 126,000 total net customer additions -- 68,000 IPTV and 58,000 high-speed Internet
• Co reaffirms guidance for FY15, sees EPS of C$3.28-3.38 vs. C$3.31 Capital IQ Consensus Estimate; reaffirms revenue growth of 1-3%.

7:11 am Alaska Comms beats by $0.06, reports revs in-line; reaffirms FY15 revs guidance; CFO and Chief Revenue Officer separate from the company (ALSK) :

• Reports Q3 (Sep) earnings of $0.02 per share, $0.06 better than the single analyst estimate of ($0.04); revenues fell 30.2% year/year to $54.74 mln vs the $54.79 mln single analyst estimate.
• Co reaffirms guidance for FY15, sees FY15 revs of $220 mln vs. $232.12 mln single analyst estimate.
• On November 4, 2015, Wayne Graham, Chief Financial Officer, and the Company, agreed that that Mr. Graham would separate from the Company effective November 30, 2015. Additionally, on November 4, 2015, David Eisenberg, Chief Revenue Officer and the Company agreed that Mr. Eisenberg would separate from the Company effective November 30, 2015. The Company also appointed Laurie Butcher, Senior Vice President, Finance, to serve as the Company's primary financial and accounting officer effective on November 5, 2015

7:11 am Main Street Capital COO Dwayne L. Hyzak given additional role as President of Co. (MAIN) :  

7:11 am Enbridge misses by $0.02; guides FY15 EPS below consensus (ENB) :

• Reports Q3 (Sep) earnings of CC$0.47 per share, CC$0.02 worse than the Capital IQ Consensus of CC$0.49.
• Co issues downside guidance for FY15, sees EPS at lower end of prior guidance of C$2.05-2.35 vs. C$2.22 Capital IQ Consensus Estimate.

7:10 am CyrusOne beats by $0.03, beats on revs; raises FY15 FFO above consensus, reaffirms FY15 rev, EBITDA (CONE) :

• Reports Q3 (Sep) funds from operations of $0.57 per share, $0.03 better than the Capital IQ Consensus of $0.54; revenues rose 31.1% year/year to $111.2 mln vs the $108.65 mln Capital IQ Consensus.
• Co issues guidance for FY15, sees FFO of $2.11-2.15 from $2.07-2.13, excluding non-recurring items, vs. $2.08 Capital IQ Consensus Estimate; reaffirms FY15 revs of $398-404 mln vs. $398.90 mln Capital IQ Consensus Estimate.

7:10 am Rice Midstream Partners reports EPS in-line, beats on revs (RMP) :

• Reports Q3 (Sep) earnings of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; revenues rose 1156.3% year/year to $20.1 mln vs the $19.6 mln Capital IQ Consensus. 
• Average daily throughput for the third quarter was 671 MDth/d, a 3% increase relative to second quarter 2015.
• "We expect to increase distributions by $0.003 per unit in the fourth quarter 2015 to $0.1965 per unit, which represents a 5% increase above our minimum quarterly distribution of $0.1875/unit"

7:09 am HHGregg misses by $0.01, reports revs in-line (HGG) :

• Reports Q2 (Sep) loss of $0.37 per share, $0.01 worse than the Capital IQ Consensus of ($0.36); revenues fell 3.4% year/year to $488.9 mln vs the $488.24 mln Capital IQ Consensus.
• Comparable store sales decreased 3.5% compared to the prior year second quarter, but improved by 280 basis points as compared to the first quarter of fiscal 2016.
• "We remain on track to meet or exceed our three key financial objectives for the year, which are focused on driving improvements for comparable store sales, cost savings and positive EBITDA for the fiscal year. We were pleased with the continued traction in our net sales during the second quarter driven by delivering on our fiscal 2016 revenue generation initiatives. In addition, we have continued our cost savings efforts and remain on track to meet our plan to save $50 million in fiscal 2016. The steady progress we have made with our transformation plan has positioned our company well as we embark on the holiday season."

7:09 am Sarepta Therapeutics reports EPS in-line (SRPT) :

• Reports Q3 (Sep) loss of $1.11 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($1.11).
  • Co said, "We are encouraged by the established body of clinical, biochemical and safety data for eteplirsen, which we plan to present at the tentatively scheduled Advisory Committee meeting in January".

7:09 am Consolidated Comms Illinois misses by $0.01, misses on revs (CNSL) :

• Reports Q3 (Sep) earnings of $0.18 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.19; revenues rose 30.2% year/year to $194 mln vs the $200.92 mln Capital IQ Consensus.
• The Company is reiterating its full year guidance:
  • Cash Interest Expense $76.5 million to $77.5 million (2014 pro forma results $81.4 million)
  • Cash Income Taxes $2.0 million to $3.0 million (2014 $12.4 million)
  • Capital Expenses $128.0 million to $132.0 million (2014 $131.3 million)

7:07 am ComScore beats by $0.03, misses on revs; guides Q4 revs below consensus; announces that Adobe is acquiring its enterprise analytics technology, Digital Analytix (SCOR) :

• Reports Q3 (Sep) earnings of $0.43 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.40; revenues rose 12.5% year/year to $92.41 mln vs the $93.93 mln Capital IQ Consensus.
• Co issues downside guidance for Q4, sees Q4 revs of $95-103 mln vs. $103.2 mln Capital IQ Consensus Estimate.
• Co also announces that Adobe (ADBE) is acquiring its enterprise analytics technology, Digital Analytix. SCOR says this divesture improves its competitive position, allowing complete focus on its mission to make audiences and advertising more valuable across all the screens that matter.
• Note: Co announced in September that it is merging with Rentrak (RENT).

7:07 am Engility misses by $0.03, misses on revs; guides FY15 EPS in-line, revs in-line (EGL) :

• Reports Q3 (Sep) earnings of $0.61 per share, $0.03 worse than the Capital IQ Consensus of $0.64; revenues rose 65.2% year/year to $570 mln vs the $589.45 mln Capital IQ Consensus.
• Co narrows guidance for FY15, sees EPS of $2.05-2.35 vs. $2.15 Capital IQ Consensus Estimate; sees FY15 revs of $2.05-2.10 bln vs. $2.14 bln Capital IQ Consensus Estimate.

7:07 am Agios Pharma misses by $0.31; new AG-122 and AG-120 data at ASH next month (abrtacts out today) (AGIO) :

• Reports Q3 (Sep) loss of $1.07 per share, $0.31 worse than the Capital IQ Consensus of ($0.76). 
• New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting (absrtacts are out today)
  
• Agios is reiterating that it expects to end 2015 with more than $350.0 million of cash, cash equivalents and marketable securities. The anticipated year end 2015 cash position does not include any additional program-specific milestone payments. Agios expects that its cash, cash equivalents and marketable securities would be sufficient to fund its operating expenses and capital expenditure requirements until late 2017.

7:07 am Shutterstock beats by $0.01, reports revs in-line; reaffirms FY15 revs guidance (SSTK) :

• Reports Q3 (Sep) earnings of $0.28 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.27; revenues rose 28.2% year/year to $107.3 mln vs the $106.46 mln Capital IQ Consensus. Co adjusted EBITDA increased 11% to $19.6 million. Paid downloads increased 22% and revenue per download increased 4%. Co FY15 adjusted EBITDA of $82-85 mln.
• Co reaffirms guidance for FY15, sees FY15 revs of $425-430 mln vs. $425.91 mln Capital IQ Consensus Estimate. 

7:06 am OncoMed Pharma misses by $0.05, misses on revs (OMED) :

• Reports Q3 (Sep) loss of $0.81 per share, $0.05 worse than the Capital IQ Consensus of ($0.76); revenues fell 75.3% year/year to $4.7 mln vs the $5.84 mln Capital IQ Consensus. 
• Tarextumab (anti-Notch 2/3, OMP-59R5) Completed enrollment in the randomized Phase 2 ALPINE pancreatic cancer trial in August. A readout of the trial data, including overall survival results from both intent-to-treat and Notch3 biomarker populations, is anticipated in the second half of 2016.
• Wnt Pathway Programs Delivery of opt-in packages to Bayer for both vantictumab and ipafricept is now anticipated in late 2016/early 2017.
• Immuno-oncology Research Advanced preclinical testing of an immuno-oncology antibody under the collaboration with Celgene with goal of achieving formal designation as a clinical development candidate in the collaboration by the end of 2015 followed by an IND filing in 2016.

7:05 am Sunesis Pharma beats by $0.03, misses on revs (SNSS) :

• Reports Q3 (Sep) loss of $0.09 per share, $0.03 better than the Capital IQ Consensus of ($0.12); revenues fell 20.0% year/year to $0.68 mln vs the $1.05 mln Capital IQ Consensus.

7:04 am Lifetime Brands misses by $0.16, misses on revs (LCUT) :

• Reports Q3 (Sep) earnings of $0.41 per share, $0.16 worse than the single analyst estimate of $0.57; revenues rose 0.6% year/year to $163.2 mln vs the $167.11 mln single analyst estimate.
• "As a result, we are revising our guidance for full-year 2015 results. We now foresee reported net sales to increase 2% to 3% year-over-year. We expect our operating margin to be in the range of 4.0 to 4.5%."

7:04 am GasLog misses by $0.03, misses on revs (GLOG) :

• Reports Q3 (Sep) loss of $0.05 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of ($0.02); revenues rose 6.4% year/year to $105.8 mln vs the $107.08 mln Capital IQ Consensus.
• The decrease in Adjusted EPS is attributable to the decrease in Adjusted Profit, the increase in Profit attributable to non-controlling interest and the dividend on preferred stock.
• There were 1,568 operating days for the quarter ended Sept 30, 2015, as compared to 1,371 operating days for the quarter ended September 30, 2014.
  • "The increase in operating days resulted from the new vessel deliveries and on-the-water vessel acquisitions during the previous periods. Specifically, we took delivery of the GasLog Saratoga on December 16, 2014, we acquired the Methane Becki Anne and the Methane Julia Louise on March 31, 2015 and we took delivery of the GasLog Salem on April 30, 2015. Profit was $4.9 million for the quarter ended Sept 30, 2015 ($31.0 million for the quarter ended Sept 30, 2014)."
• This decrease is mainly attributable to the increase in loss on swaps, increased financial costs derived from higher average outstanding debt, increased depreciation and operating expenses due to the increased fleet and decreased daily hire rate resulting from the vessels operating in the current weak spot market.

  
  

7:03 am Noodles & Co misses by $0.06, misses on revs; guides FY15 EPS below consensus, revs below consensus (NDLS) :

• Reports Q3 (Sep) adjusted EPS of $0.00, $0.06 worse than the Capital IQ Consensus of $0.06; revenues rose 10.5% year/year to $117.3 mln vs the $119.77 mln Capital IQ Consensus.
  • Comparable restaurant sales decreased 0.7% for company-owned restaurants, decreased 1.9% for franchise restaurants and decreased 0.9% system-side.
  • 16 new restaurants opened system-wide in the third quarter, including 13 company-owned and three franchise restaurants.
• Co issues downside guidance for FY15, sees EPS of $0.13-0.15 vs. $0.28 Capital IQ Consensus Estimate; sees FY15 revs of $455 mln vs. $462.14 mln Capital IQ Consensus Estimate.

7:03 am Kate Spade beats by $0.02 (KATE) :

• Reports Q3 (Sep) earnings of $0.06 per share, $0.02 better than the Capital IQ Consensus of $0.04; adj. revenues rose 26.1% year/year to $275 mln (GAAP rev +1.7% to $277 mln) vs the $279.7 mln Capital IQ Consensus. 
• Third quarter 2015 direct-to-consumer comparable sales growth was 16%, or 11% excluding eCommerce. Comparable sales per square foot for kate spade new york stores were $1,504 for the latest twelve months, compared to $1,495 for the twelve month period ended July 4, 2015.

7:03 am TransCanada announces adjustments to the Energy East Pipeline Project (TRP) : The company will be amending the Energy East application before the National Energy Board to remove a port in Quebec from the scope of the project.

7:03 am Gartner beats by $0.03, misses on revs; guides FY15 revs in-line (IT) :

• Reports Q3 (Sep) earnings of $0.45 per share, $0.03 better than the Capital IQ Consensus of $0.42; revenues rose 6.2% year/year to $500.2 mln vs the $509.2 mln Capital IQ Consensus.
• Co issues in-line guidance for FY15, sees FY15 revs of $2.15-2.19 bln vs. $2.17 bln Capital IQ Consensus Estimate.

7:02 am RXi Pharma initiates a Phase 1/2 clinical trial of RXI-109, as a potential treatment to prevent the progression of retinal scarring (RXII) : The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring. The safety and tolerability of RXI-109, as well as the potential for clinical activity, will be evaluated over the course of the study using numerous assessments to monitor ocular health and visual acuity. Several dose levels will be evaluated in a small number of subjects in this first trial in order to establish safety information and to help determine the dosing regimen for continued study.

7:02 am Bristol-Myers announces that the EMA validated a type II variation application, which seeks to extend the current indication for Opdivo to include the treatment of adult patients with advanced renal cell carcinoma after prior therapy (BMY) :

Co announces that the EMA validated a type II variation application, which seeks to extend the current indication for Opdivo to include the treatment of adult patients with advanced renal cell carcinoma after prior therapy.

• Thus, beginning the EMA's centralized review process. The type II variation submitted is based on data from CheckMate -025, a Phase 3 study that evaluated, as the primary endpoint, the overall survival of Opdivo versus everolimus, a current standard of care, in advanced or metastatic clear-cell RCC after prior anti-angiogenic treatment.

7:02 am Oasmia Pharmaceutical confirms the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane, demonstrated superimposable paclitaxel PK profiles (OASM) : Oasmia believes that results from this study strengthen its position for rapid growth among competitors within the oncology sector, including Celgene Corporation and Sorrento Therapeutics, Inc. "Statistical analysis demonstrated the two formulations to be bioequivalent with regard to drug concentrations. The bioequivalence demonstrated for unbound paclitaxel is of particular importance, since it is this concentration that is related to clinical effects. Also, the ratio between unbound and total drug showed bioequivalence."

7:01 am Dynavax beats by $0.01, misses on revs (DVAX) :

• Reports Q3 (Sep) loss of $0.82 per share, $0.01 better than the two analyst estimate of ($0.83); revenues fell 45.5% year/year to $1.2 mln vs the $1.65 mln Capital IQ Consensus.

7:01 am BioCryst Pharma reports EPS in-line, beats on revs (BCRX) :

• Reports Q3 (Sep) loss of $0.20 per share, in-line with the Capital IQ Consensus of ($0.20); revenues rose 243.8% year/year to $11 mln vs the $7.47 mln Capital IQ Consensus. The increase in revenue was the result of higher levels of product and collaboration revenue associated with the sale of RAPIVAB (peramivir injection) and the Seqirus, formerly bioCSL, out-licensing transaction, as well as increased collaboration revenue associated with BCX4430 development as a medical counter measure for Ebola virus and other filovirus diseases. 
• BioCryst recently announced that the OPuS-2 (Oral ProphylaxiS-2) clinical trial of avoralstat completed enrollment of approximately 100 HAE patients, and the Company expects to report results in early Q1 2016.
• The APeX-1 (Angioedema ProphylaXis) Phase 2, four week dose ranging trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BCX7353 as a preventative treatment to reduce or eliminate attacks in HAE patients is expected to begin by early 2016, with results expected mid-2016.

Financial Outlook for 2015

• Based upon current trends, assumptions, and development plans, BioCryst expects its 2015 net operating cash use to be in the range of $8 to $18 million, upon adjusting the Company's previously predicted range for the first nine months of operations and including the favorable impact of the Seqirus transaction. In addition, BioCryst continues to expect its operating expenses to be within the range of $75 to $95 million. Our operating expense range excludes equity-based compensation expense due to the difficulty in accurately projecting this expense, as it is significantly impacted by the volatility and price of the Company's stock, as well as vesting of the Company's outstanding performance-based stock options.

7:00 am Geo Group beats by $0.16, misses on revs; guides Q4 FFO above consensus, revs above consensus (GEO) :

• Reports Q3 (Sep) funds from operations of $0.90 per share, $0.16 better than the Capital IQ Consensus of $0.74; revenues rose 2.6% year/year to $469.86 mln vs the $479.18 mln Capital IQ Consensus.
• Co issues upside guidance for Q4, sees FFO of $0.91-0.93 vs. $0.76 Capital IQ Consensus Estimate; sees Q4 revs of $512-517 mln vs. $508.11 mln Capital IQ Consensus Estimate.

7:00 am Teradata reports EPS in-line, misses on revs; guides FY15 EPS below consensus, revs below consensus; will realign cost structure (TDC) :

• Reports Q3 (Sep) earnings of $0.55 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.55; revenues fell 9.1% year/year to $606 mln vs the $638.37 mln Capital IQ Consensus.
• Co issues downside guidance for FY15, sees EPS of $2.00-2.20, excluding non-recurring items, vs. $2.23 Capital IQ Consensus Estimate; sees FY15 revenue decline of 6-8% which we compute as $2.51-2.57 bln vs. $2.58 bln Capital IQ Consensus Estimate.
• Teradata is also rationalizing its cost structure to better align its infrastructure, research and development and go-to-market resources for improved efficiency, effectiveness and profitability. Additionally, Teradata plans to exit the Marketing Application business to allow the company to focus exclusively on improving and growing its Data and Analytics business. Combining the cost reduction initiatives and the exit of the Marketing Applications business, Teradata currently expects a benefit of approximately $120 million in operating income in 2016, exclusive of one-time costs.

6:58 am Visteon beats by $0.26, beats on revs; guides for FY15 (VC) :

• Reports Q3 (Sep) earnings of $0.56 per share, excluding non-recurring items, $0.26 better than the Capital IQ Consensus of $0.30; revenues rose 1.9% year/year to $808 mln vs the $753.25 mln Capital IQ Consensus.
• The company projects 2015 sales for the Electronics Product Group of $3.05-3.10 bln.
• Adjusted EBITDA for the Electronics Product Group and Corporate costs is projected in the range of $265 mln-285 mln.
• Adjusted free cash flow for the Electronics Product Group and Corporate costs is projected in the range of $135-165 mln.

6:58 am Cedar Fair misses by $0.61, beats on revs; increases quarterly dividend 10% (FUN) :

• Reports Q3 (Sep) earnings of $2.92 per share, $0.61 worse than the Capital IQ Consensus of $3.53; revenues rose 8.3% year/year to $644.6 mln vs the $633.34 mln Capital IQ Consensus. 
• Board of Directors declared a 10% increase in the Company's quarterly cash distribution to $0.825 per limited partner unit, payable December 15, 2015.

6:57 am Rice Energy announces that Rice Midstream Partners (RMP) has acquired its subsidiary's water services business for $200 mln, plus a $25 mln earn-out (RICE) :

Co announced that Rice Midstream Partners (RMP) has acquired the water services business of Rice's wholly-owned subsidiary, Rice Midstream Holdings, for $200 million at closing plus a $25 million earn out to be paid upon achievement of certain increases in connected water sources. Midstream Holdings received $200 million of proceeds, which was used to repay borrowings outstanding under its revolving credit facility, resulting in an undrawn credit facility with $300 million of availability.Subsequently, Midstream Holdings distributed $43 million to Rice to be used for general corporate purposes.

• Also, RMP priced a private placement of 13,409,961 common units for gross proceeds of $175 million and announced increased 2015 guidance.

6:57 am Insys Therapeutics beats by $0.27, beats on revs; announces CEO Babich steps down, Board authorizes $50 mln repurchase (INSY) :

Reports Q3 (Sep) earnings of $0.50 per share, $0.27 better than the Capital IQ Consensus of $0.23; revenues rose 56.6% year/year to $91.26 mln vs the $82.99 mln Capital IQ Consensus.

• Management changes and appointments:
  • Michael L. Babich has stepped down as President and Chief Executive Officer of Insys.
  • The Board of Directors has appointed Dr. John N. Kapoor as Chairman, President and Chief Executive Officer.
  • Daniel Brennan, has been appointed Executive Vice President and Chief Operating Officer effective November 1, 2015.
• The Board of Directors approved the repurchase of up to $50 million of the Company's common stock;
• "In addition to realizing the full potential of Subsys, we are focused on progressing our robust portfolio of product candidates. The most advanced of our candidates is our Dronabinol Oral Solution, which we expect will be branded Syndros, for which our NDA was accepted by the FDA for filing in August 2015. We are preparing for potential regulatory approval and commercial launch during spring 2016, if approved by the FDA."

6:56 am ReWalk misses by $0.04, beats on revs (RWLK) :

• Reports Q3 (Sep) loss of $0.53 per share, $0.04 worse than the Capital IQ Consensus of ($0.49); revenues fell 20.0% year/year to $1.2 mln vs the $1.13 mln two analyst estimate. 
• Placed 23 ReWalk systems during the third quarter of 2015 compared to 27 systems during the prior year quarter; and up sequentially from the 12 systems placed during the second quarter of 2015.

6:55 am OGE Energy misses by $0.01, misses on revs; guides FY15 to low end of range (OGE) :

• Reports Q3 (Sep) earnings of $0.90 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.91; revenues fell 4.6% year/year to $719.8 mln vs the $767.4 mln single analyst estimate.
• Co issues downside guidance for FY15, sees EPS at the low end of $1.76-1.89 vs. $1.86 Capital IQ Consensus Estimate.

6:54 am Laredo Petroleum beats by $0.01, misses on revs (LPI) :

• Reports Q3 (Sep) earnings of $0.07 per share, $0.01 better than the Capital IQ Consensus of $0.06; revenues fell 24.9% year/year to $150.34 mln vs the $154.64 mln Capital IQ Consensus. 
• Produced 44,820 barrels of oil equivalent ("BOE") per day, up approximately 16% from the comparable third quarter of 2014 Reduced unit cash costs to $12.15 per BOE, a decrease of approximately 28% from the third-quarter 2014 rate of $16.76 per BOE, on a three-stream basis. 
• Q4 Production
  • Production (:MMBOE) 3.6-3.8 (45% crude, 27% LNG, 28% nat gas)
  • Lease operating expenses $6.25-7.25
• CapEx
  • Through the nine months ended September 30, 2015, the Company has invested approximately $398 million in exploration and development activities and approximately $130 million in the Medallion pipeline system and other pipeline and related infrastructure assets held by LMS. Laredo expects to invest a total of approximately $650 million in 2015, including investments in the Medallion pipeline system.

6:53 am Chatham Lodging misses by $0.01; guides Q4 FFO below consensus (CLDT) :

• Reports Q3 (Sep) funds from operations of $0.76 per share, $0.01 worse than the Capital IQ Consensus of $0.77.
• Co issues downside guidance for Q4, sees FFO of $0.42-0.44 vs. $0.48 Capital IQ Consensus Estimate.

6:52 am Inland Real Estate beats by $0.01, reports revs in-line; guides FY15 FFO below consensus (IRC) :

• Reports Q3 (Sep) funds from operations of $0.25 per share, $0.01 better than the Capital IQ Consensus of $0.24; revenues rose 0.1% year/year to $48.24 mln vs the $48.3 mln single analyst estimate.
• Co issues downside guidance for FY15, sees FFO of $0.96-0.98 vs. $0.99 Capital IQ Consensus Estimate, prior range $0.96-1.00

6:52 am Insys Therapeutics announces $50 mln repurchase program (INSY) :  

6:51 am Insys Therapeutics announces that Michael L. Babich has stepped down as President and CEO; Dr. John N. Kapoor appointed President and CEO (INSY) :

Babich has stepped down as President and CEP of Insys.

• The BOD has appointed Dr. John N. Kapoor as President and CEO effective November 4, 2015

6:51 am Molson Coors Brewing beats by $0.11, reports revs in-line; appoints CFO of European unti to CFO (TAP) :

• Reports Q3 (Sep) earnings of $1.40 per share, $0.11 better than the Capital IQ Consensus of $1.29; revenues fell 12.9% year/year to $1.02 bln vs the $1.02 bln Capital IQ Consensus. 
• Underlying EBITDA was $420.2 million in the third quarter, a 10.4 percent decrease from a year ago due to unfavorable foreign currency movements and terminated contracts.
• Co reported a 4.3 percent decrease in underlying after-tax income for the third quarter 2015, driven by unfavorable foreign currency movements, increased brand investments, and the termination of our Miller brands agreement in Canada and the Modelo brands and Heineken brewing contracts in the U.K. this year.
• Worldwide volume increased 0.7 percent, driven by strong growth in Europe and International.
• David Heede, currently Chief Financial Officer, Molson Coors Europe (:MCE), has been appointed to the role of Chief Financial Officer, Molson Coors, on an interim basis, effective 16 November 2015.

6:51 am Houghton Mifflin Harcourt misses by $0.11, misses on revs; lowers FY15 revs guidance; adds $500 mln to repurchase program (HMHC) :

• Reports Q3 (Sep) earnings of $0.94 per share, $0.11 worse than the Capital IQ Consensus of $1.05; revenues rose 4.4% year/year to $575.51 mln vs the $654.01 mln Capital IQ Consensus.
• Co lowersguidance for FY15, sees FY15 revs of $1.415-1.45 bln (+3-6% y/y vs. previously seeing 9-12% increase) vs. $1.51 bln Capital IQ Consensus Estimate.
• On November 3rd, the HMH Board of Directors authorized an increase in the size of its existing share repurchase program by an additional $500 million for an aggregate total of $1 billion.
• Additionally, subject to market and other conditions, the Company plans to increase its debt by an additional $250 million and use some or all of the net proceeds from the financing to fund a portion of its share repurchases under the share repurchase program among other general corporate purposes.

6:50 am Stantec reports EPS in-line, beats on revs (STN) :

• Reports Q3 (Sep) earnings of CC$0.53 per share, in-line with the Capital IQ Consensus of CC$0.53; revenues rose 11.3% year/year to CC$750.8 mln vs the CC$623.46 mln Capital IQ Consensus.

6:49 am New York REIT misses by $0.02, beats on revs (NYRT) :

• Reports Q3 (Sep) funds from operations of $0.11 per share, $0.02 worse than the Capital IQ Consensus of $0.13; revenues rose 10.1% year/year to $44.6 mln vs the $43.61 mln Capital IQ Consensus.

6:48 am Triple-S Management beats by $0.07, reports revs in-line (GTS) :

• Reports Q3 (Sep) earnings of $0.39 per share, $0.07 better than the two analyst estimate of $0.32; revenues rose 32.8% year/year to $765.1 mln vs the $772.38 mln two analyst estimate.
• "Despite a challenging environment, we posted better-than-expected third-quarter financial results. During the period, our Managed Care and Property & Casualty segments demonstrated further improvement in their ongoing operating performance. Specifically, Medicare premiums increased 13% in the period, while Property & Casualty operating income rose 13%, yielding a double-digit operating margin. We also continued to repurchase our common stock in the open market, buying back 683,000 shares this quarter."

6:48 am Stantec announces a normal course issuer bid for up to 3,774,179 common shares; firm also to acquire the Infrastructure Americas Division of KBR (KBR) (STN) : Co announced today that its Notice of Intention to make a Normal Course Issuer Bid has been filed with and approved by the Toronto Stock Exchange. Pursuant to the Notice, Stantec may purchase up to 3,774,179 common shares. It also announced the planned acquisition of the Infrastructure Americas Division of KBR (KBR), expected to close in December 2015. The transaction price was $19 mln. 

6:47 am U.S. Concrete beats by $0.87, beats on revs (USCR) :

• Reports Q3 (Sep) earnings of $1.97 per share, excluding non-recurring items, $0.87 better than the Capital IQ Consensus of $1.10; revenues rose 49.4% year/year to $295.11 mln vs the $282.38 mln Capital IQ Consensus.

6:47 am Denbury Resources beats by $0.05, misses on revs; lowers produiction gudiance, cap-ex (DNR) :

• Reports Q3 (Sep) earnings of $0.18 per share, $0.05 better than the Capital IQ Consensus of $0.13; revenues fell 52.4% year/year to $303.6 mln vs the $455.93 mln Capital IQ Consensus. 
  • Denbury's total production for the third quarter of 2015 averaged 71,410 BOE/d, which included 40,834 Bbls per day ("Bbls/d") from tertiary properties and 30,576 BOE/d from non-tertiary properties. Total production during the third quarter of 2015 decreased 3% QoQ and YoY
• Company currently estimates total annual production volumes will average in the lower half 72.5-75.5 MBOE/d of the Company's prior estimated total production range.
• In the second half of 2015, the Company has reduced its estimated 2015 development capital expenditure budget by $95 million, offset in part by higher capitalized interest, lowering its overall 2015 estimated capital spending budget to $475 million, down from the previously estimated total capital spending amount of $550 million.  

6:47 am Enbridge acquires 24.9% interest in the 400 megawatt Rampion Offshore Wind Project in the UK for CAD $750 mln; will manage construction of the project (ENB) :  

6:46 am Loxo Oncology announces that Chief Medical Officer Jennifer Low will leave the company (LOXO) : Co announced that Jennifer Low, M.D., Ph.D., chief medical officer and executive vice president, R&D, has decided to transition from her current role with Loxo Oncology. Over the next several months, Dr. Low will remain at Loxo Oncology as acting chief medical officer, as an employee through the end of 2015 and in an advisory role thereafter.

6:46 am Market View: Dec. E-mini stock-index futures to to new pre-market highs in recent trade with ESz5 now +7.25, YMz5 now +58, & NQz5 now +14.50 (:TECHX) :  

6:46 am Starwood Property Trust beats by $0.03, reports revs in-line; narrows FY15 EPS guidance (STWD) :

• Reports Q3 (Sep) earnings of $0.56 per share, $0.03 better than the Capital IQ Consensus of $0.53; revenues rose 5.9% year/year to $192.15 mln vs the $193.09 mln Capital IQ Consensus.
• Co issues in-line guidance for FY15, sees EPS of $2.13-2.17 (prior $2.05-2.25) vs. $2.16 Capital IQ Consensus Estimate.
• Subsequent to July 1, 2015, the Company entered into definitive agreements to acquire 30 affordable housing communities located throughout Florida for an aggregate acquisition price of $553.2 million.

6:45 am Ametek increases its share repurchase authorization by $350 mln, to be added to the $90 mln current authority (AME) :  

6:43 am Mitel Networks beats by $0.04, misses on revs; guides Q4 EPS above consensus, revs in-line (MITL) :

• Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.08; revenues fell 30.0% year/year to $190.7 mln vs the $285.19 mln Capital IQ Consensus.
• Co issues guidance for Q4, sees EPS of $0.22-0.27 vs. $0.19 Capital IQ Consensus Estimate; sees Q4 revs of $315-340 mln vs. $320.52 mln Capital IQ Consensus Estimate.

6:43 am Penn West Energy beats by $0.26, beats on revs (PWE) :

• Reports Q3 (Sep) earnings of CC$0.09 per share, CC$0.26 better than the single analyst estimate of (CC$0.17); revenues fell 49.9% year/year to CC$295 mln vs the CC$285.28 mln single analyst estimate.

6:43 am Albemarle agrees to sell its Tribotecc metal sulfides business to Treibacher Industrie AG for undisclosed sum; expected to close by the end of 2015 (ALB) :  

6:42 am CenterPoint beats by $0.05, misses on revs; raises low end of FY15 EPS guidance (CNP) :

• Reports Q3 (Sep) earnings of $0.34 per share, $0.05 better than the Capital IQ Consensus of $0.29; revenues fell 9.8% year/year to $1.63 bln vs the $1.98 bln Capital IQ Consensus.
• Co issues in-line guidance for FY15, sees EPS of $1.05-1.10 (prior $1.00-1.10) vs. $1.05 Capital IQ Consensus Estimate.
• CenterPoint Energy is targeting 4-6 percent earnings per share annual growth through 2018 on a guidance basis, inclusive of midstream investments.

6:42 am Madison Square Garden beats by $0.57, beats on revs; announces $525 mln buyback and 20 year media rights agreements for New York Knicks and Rangers with MSG Networks (MSG) :

• Reports Q1 (Sep) loss of $0.06 per share, $0.57 better than the Capital IQ Consensus of ($0.63); revenues rose 26.5% year/year to $150.38 mln vs the $135.4 mln Capital IQ Consensus.
  • The Madison Square Garden Company's board authorized the repurchase of up to $525 million of the Company's Class A common stock.
  • The Company has entered into 20-year media rights agreements with MSG Networks Inc. for the New York Knicks and the New York Rangers, which provide MSG Networks Inc. with exclusive local media rights to team games. Under these media rights agreements, the Company expects to recognize rights fee revenue of approximately $130 million for fiscal 2016, which would be approximately $49 million more than the intercompany rights fee revenue reflected in the Company's financial statements for fiscal 2015.

6:41 am ITC Holdings reports EPS in-line, misses on revs; reaffirms FY15 EPS guidance (ITC) :

• Reports Q3 (Sep) earnings of $0.53 per share, in-line with the Capital IQ Consensus of $0.53; revenues rose 1.1% year/year to $273.2 mln vs the $294.38 mln Capital IQ Consensus.
• Co reaffirms guidance for FY15, sees EPS of $2.00-2.15 vs. $2.07 Capital IQ Consensus Estimate. 
  • ITC is revising its 2015 capital guidance range to a range of $715 to $765 mln from the previous range of $710 to $810 mln. The revised range includes $180 to $190 mln for ITCTransmission, $155 to $170 mln for METC, $370 to $385 mln for ITC Midwest, $10 to $15 mln for ITC Great Plains and up to $5 mln of Development and Other.

6:40 am MSG Networks beats by $0.05, reports revs in-line (MSGN) :

• Reports Q1 (Sep) earnings of $0.54 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.49; revenues rose 3.8% year/year to $148.1 mln vs the $147.1 mln Capital IQ Consensus. Affiliation fee revenue increased $4.8 million, primarily due to higher affiliation rates, partially offset by the impact of a low single digit percentage decrease in subscribers versus the prior year period. Advertising revenue was essentially flat.
• Adjusted operating cash flow -17% to $51.2 million and operating income flat at $42.2 million from continuing operations.

6:38 am HollyFrontier beats by $0.11, beats on revs (HFC) :

• Reports Q3 (Sep) earnings of $1.82 per share, $0.11 better than the Capital IQ Consensus of $1.71; revenues fell 32.6% year/year to $3.59 bln vs the $3.11 bln Capital IQ Consensus.

6:37 am Endo Intl beats by $0.02, beats on revs (warned in late Sept); reaffirms FY15 guidance (ENDP) :

• Reports Q3 (Sep) earnings of $1.02 per share, $0.02 better than the Capital IQ Consensus of $1.00; revenues rose 14.1% year/year to $746 mln vs the $737.65 mln Capital IQ Consensus.
• COpreannouinced Q3 rev $720-740 mln vs. $772 mln consensus on Seot 28.
  
  • U.S. Branded Pharmaceuticals results include: Revenues of $305 million, a 27 percent increase compared to third quarter 2014; this increase was primarily attributable to the strategic addition of Auxilium Pharmaceuticals.
  • US. Generic Pharmaceuticals results include: Net sales of $368 million, a 15 percent increase compared to third quarter 2014; this increase was attributable to underlying organic growth of the business, including new product launches, as well as growth from the addition of sales from our September 2015 acquisition of Par and our August 2014 acquisition of DAVA Pharmaceuticals.
• Co reaffirms guidance for FY15, sees EPS of $4.50-4.60, excluding non-recurring items, vs. $4.56 Capital IQ Consensus; revs of $3.22-3.27 vs. $3.27 bln Capital IQ Consensus Estimate. 
• "Following the recent FDA approval of BELBUCA, we are conducting a strategic portfolio optimization process to expand our pain sales force and reallocate resources across key growth products in our U.S. Branded Pharmaceuticals business. Moving forward, we remain focused on execution and value creation activities: the integration of Par, driving growth for our priority branded products, growing our international presence and strategic M&A." 

6:37 am Intrawest Resorts beats by $0.05, beats on revs; reaffirms FY16 revs guidance (SNOW) :

• Reports Q1 (Sep) loss of $1.04 per share, $0.05 better than the Capital IQ Consensus of ($1.09); revenues rose 2.2% year/year to $86.2 mln vs the $72.56 mln Capital IQ Consensus.
• Co reaffirms guidance for FY16, sees FY16 revs of $571-596 mln vs. $587.21 mln Capital IQ Consensus Estimate. Expects total Adjusted EBITDA to be in the range of $116 million to $121 million, and net income attributable to Intrawest Resorts Holdings, Inc. to be in the range of zero to $10 million.

6:36 am Essent Group reports EPS in-line (ESNT) :

• Reports Q3 (Sep) earnings of $0.44 per share, in-line with the Capital IQ Consensus of $0.44.

6:36 am ITT Educational beats by $0.01, misses on revs (ESI) :

• Reports Q3 (Sep) earnings of $0.07 per share, $0.01 better than the Capital IQ Consensus of $0.06; revenues fell 16.2% year/year to $203.2 mln vs the $208.93 mln Capital IQ Consensus.
• New student enrollment in the third quarter of 2015 decreased 18.4% to 14,943 compared to 18,317 in the same period in 2014. Total student enrollment decreased 15.5% to 48,231 as of September 30, 2015 compared to 57,101 as of September 30, 2014. 

6:33 am Virtusa agrees to acquire majority interest in Polaris Consulting & Services, Ltd. for ~$270 mln; estimated to be (-$0.08) dilutive to 4Q16 EPS and slightly dilutive FY 2017 EPS and accretive thereafter (VRTU) :

Co agrees to acquire a majority interest in Polaris Consulting & Services, Ltd. for ~$270 mln.

• The transaction consideration includes both the 51.7% majority interest and an unconditional mandatory open offer to purchase up to 26% of the outstanding shares of Polaris.
• The Polaris transaction is expected to close during Co's 4Q.
• On a non-GAAP basis, transaction is estimated to be ($0.08) dilutive to fiscal 4Q16 EPS, slightly dilutive to fiscal year 2017 EPS, and accretive thereafter.

6:33 am SeaWorld Entertainment misses by $0.04, misses on revs (SEAS) :

• Reports Q3 (Sep) earnings of $1.14 per share, $0.04 worse than the Capital IQ Consensus of $1.18; revenues rose 0.2% year/year to $496.9 mln vs the $508.51 mln Capital IQ Consensus.
• Updated full year 2015 Adjusted EBITDA guidance to be in the range of $360 million to $370 million. The Company also updated its 2015 capital expenditures guidance to be in the range of $165 million to $175 million. C 
• "Looking ahead, we have developed a comprehensive strategic plan to build on our unique strengths, to overcome our challenges and to execute a disciplined approach to cost management and use of cash. We look forward to sharing additional information during our upcoming webcast on November 9, on how we will execute to achieve our objectives and generate a sustainable increase in shareholder value." 

6:33 am Cinemark misses by $0.03, beats on revs (CNK) :

• Reports Q3 (Sep) earnings of $0.40 per share, $0.03 worse than the Capital IQ Consensus of $0.43; revenues rose 8.2% year/year to $700.1 mln vs the $678.09 mln Capital IQ Consensus. Adjusted EBITDA for Q3 increased 9.2% to $154.8 million from $141.7 million for Q3 of last year.
• Attendance increased 7.3% to 71.0 million patrons.
  

6:30 am Quanta Services beats by $0.01, reports revs in-line; guides Q4 ~in-line (PWR) :

• Reports Q3 (Sep) earnings of $0.30 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.29; revenues fell 9.6% year/year to $1.94 bln vs the $1.94 bln Capital IQ Consensus.
• Co issues in-line guidance for Q4, sees EPS of $0.26-0.32, excluding non-recurring items, vs. $0.32 Capital IQ Consensus Estimate; sees Q4 revs of $1.75-1.85 bln vs. $1.78 bln Capital IQ Consensus Estimate. 
• "While our results for the third quarter and the first nine months of this year have been below our expectations, the underlying drivers of our business remain intact and we are confident in opportunities for profitable growth over the next several years."

6:29 am Walter Investment Mgmt misses by $0.08, misses on revs (WAC) :

• Reports Q3 (Sep) earnings of $0.44 per share, excluding non-recurring items, $0.08 worse than the Capital IQ Consensus of $0.52; revenues fell 43.2% year/year to $219.4 mln vs the $345.33 mln Capital IQ Consensus. The Originations segment generated revenue of $132.0 mln in the third quarter of 2015.
• The Servicing segment generated total revenue of $31.2 mln in the third quarter of 2015, an 86% decline as compared to third quarter 2014.

6:28 am Orbotech beats by $0.07, beats on revs; guides Q4 revs in-line (ORBK) :

• Reports Q3 (Sep) earnings of $0.55 per share, $0.07 better than the Capital IQ Consensus of $0.48; revenues rose 13.9% year/year to $190.5 mln vs the $185.4 mln Capital IQ Consensus.
• Co issues in-line guidance for Q4, sees Q4 revs of $184-192 mln vs. $187.81 mln Capital IQ Consensus Estimate.

6:28 am Olympic Steel beats by $0.04, misses on revs (ZEUS) :

• Reports Q3 (Sep) loss of $0.05 per share, $0.04 better than the two analyst estimate of ($0.09); revenues fell 26.5% year/year to $276.9 mln vs the $319.63 mln single analyst estimate.
• "In anticipation of this market environment, our disciplined approach has generated cash flow from operations of more than $69 million since the beginning of the year... This has enabled us to eliminate $60 million in debt under our low-cost, flexible credit facility, and authorize a share repurchase program."

6:27 am On the Wires (:WIRES) :

• Cone Midstream Partners (CNNX) disclosed in a regulatory filing that effective November 4, 2015, C. Kristopher Hagedorn resigned as Chief Accounting Officer to focus on his new and increased responsibilities as Vice President and Controller of CONSOL Energy (CNX). Effective November 4, 2015, the Board of Directors of the General Partner appointed Brian Robert Rich as Chief Accounting Officer of the General Partner.
• Statoil (STO) has awarded contracts for the catering and facilities services for its UK offshore and onshore operations to ESS Offshore and 14forty, both part of Compass Group (CMPGY). Each contract has a duration of five years with options to extend to up to four years.

6:26 am ChromaDex announces a registered direct offering of $2 mln in common stock, to three of its largest investors; Dr. Philip Frost, and former co-Chairmen, Barry Honig and Michael Brauser (CDXC) : The Company agreed to sell a total of 200,000 units at a purchase price of $10.00 per Unit, with each Unit consisting of eight shares of the Company's common stock, par value of $0.001 per share. Proceeds from the transaction will be used for additional working capital as well as to meet stockholder equity requirements for a potential uplisting for the Company's shares on a national exchange.

6:26 am Stock Building Supply Holdings beats by $0.04, misses on revs (STCK) :

• Reports Q3 (Sep) adj. earnings of $0.30 per share, $0.04 better than the Capital IQ Consensus of $0.26; revenues rose 1.2% year/year to $358.5 mln vs the $368.98 mln Capital IQ Consensus. 
• The co estimates net sales grew approximately 4.5% related to increased volume but was largely offset by reduced selling prices on commodity products.
• "Our announced strategic merger with BMC, which significantly expands our operating footprint and adds more than $1.3 billion in annual net sales to the Company's historical financial results, remains on track to close in the fourth quarter of 2015. Furthermore, we are finalizing development and beginning the launch of our 24x7 eCommerce platform, which provides a customer portal into our ERP and eBusiness suite of services. This platform is expected to deliver meaningful improvements in customer and employee productivity. Once fully implemented across the Company, we expect that our integrated suite of eBusiness services will have a significant positive effect on our customer service, growth potential and productivity that will support continued expansion of our operating margins."

6:23 am Telus beats by $0.01, reports revs in-line; reaffirms FY15 guidance; announces additional restructuring, reducing ~1500 positions (TU) :

• Reports Q3 (Sep) earnings of CC$0.66 per share, excluding non-recurring items, CC$0.01 better than the Capital IQ Consensus of CC$0.65; revenues rose 4.2% year/year to CC$3.15 bln vs the CC$3.16 bln Capital IQ Consensus, as a result of higher data revenue in both wireless and wireline operations. Wireless data revenue increased 12 per cent from a year ago, leading to overall network revenue growth of 4.0 per cent, while wireline data revenue increased 11 per cent to generate 3.3 per cent growth in external wireline revenue.
• "We are increasing our efficiency initiatives by an additional $125 million in the fourth quarter, which will include a net reduction of ~1,500 full-time positions, a notable number of which are voluntary departures and early retirements."
• Co reaffirms guidance for FY15, sees EPS of C$2.40-2.60 vs. C$2.58 Capital IQ Consensus Estimate; EBITDA CAD$4.40-4.575 bln.

6:23 am VEREIT reports FFO in-line, beats on revs (VER) :

• Reports Q3 (Sep) funds from operations of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; revenues fell 15.8% year/year to $384.9 mln vs the $350.52 mln Capital IQ Consensus. 
• Cole Capital segment normalized EBITDA for the quarter ended September 30, 2015 decreased $20.2 million to $7.0 million as compared to normalized EBITDA of $27.2 million for the same quarter in 2014

6:22 am Hill-Rom beats by $0.08, beats on revs; guides Q1 EPS below consensus, revs in-line; guides FY16 EPS in-line, revs in-line (HRC) :

• Reports Q4 (Sep) earnings of $0.89 per share, $0.08 better than the Capital IQ Consensus of $0.81; revenues rose 19.6% year/year to $573.9 mln vs the $551.11 mln Capital IQ Consensus.
• Co issues guidance for Q1, sees EPS of $0.60-0.62 vs. $0.65 Capital IQ Consensus Estimate; sees Q1 revs of $645-655 mln vs. $653.69 mln Capital IQ Consensus Estimate.
• Co issues in-line guidance for FY16, sees EPS of $3.08-3.14 vs. $3.09 Capital IQ Consensus Estimate; sees FY16 revs of $2.66-2.70 bln vs. $2.67 bln Capital IQ Consensus Estimate.
• Hill-Rom expects cash flow from operations for the full year to be approximately $300 million, which includes non-recurring outflows related to our ongoing restructuring and integration activities. Capital expenditures are expected to be approximately $110 to $120 million.

6:19 am VWR Corp reports EPS in-line, revs in-line; reaffirms FY15 EPS guidance, revs guidance (VWR) :

• Reports Q3 (Sep) earnings of $0.38 per share, in-line with the Capital IQ Consensus of $0.38; revenues fell 1.7% year/year to $1.1 bln vs the $1.09 bln Capital IQ Consensus.
• Co reaffirms guidance for FY15, sees EPS of $1.42-1.50 vs. $1.47 Capital IQ Consensus Estimate; sees FY15 revs of $4.24-4.31 bln vs. $4.29 bln Capital IQ Consensus Estimate.

6:19 am Swift Energy misses by $0.02, beats on revs; raises FY15 production guidance (SFY) :

• Reports Q3 (Sep) loss of $0.74 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of ($0.72); revenues fell 56.7% year/year to $60.1 mln vs the $58.62 mln Capital IQ Consensus. 
• Swift Energy produced 2.87 mln barrels of oil equivalent during Q3, above the high end of the Company's guided range of 2.77 to 2.82 MMBoe. Third quarter 2015 production compares to production of 2.88 MMBoe in the second quarter of 2015.
• Guidance: Co is now targeting full year production levels of 11.6 to 11.7 MMBoe, slightly above its previously guided range of 11.5 to 11.6 MMBoe. The Company maintained its previously planned full-year capital expenditure budget of $110-$120 mln.

6:18 am Natural Gas Services beats by $0.03, reports revs in-line (NGS) :

• Reports Q3 (Sep) earnings of $0.20 per share, $0.03 better than the Capital IQ Consensus of $0.17; revenues fell 17.2% year/year to $21.2 mln vs the $21.19 mln Capital IQ Consensus, attributable to lower unit sales and a fall in rental revenue related to reduced activity in the upstream oil and gas industry due to low commodity prices.

6:17 am Time beats by $0.05, reports revs in-line; lowers high end of FY15 revs guidance; authorizes $300 mln repurchase contingent on closing of Blue Fin sale (TIME) :

• Reports Q3 (Sep) earnings of $0.32 per share, $0.05 better than the Capital IQ Consensus of $0.27; revenues fell 5.8% year/year to $773 mln vs the $769.35 mln Capital IQ Consensus.
• Co issues in-line guidance for FY15, sees FY15 revs of $3.08-3.12 bln (-6% to -5%) (Previously guided for -6% to -3$) vs. $3.1 bln Capital IQ Consensus Estimate.
• On October 30, 2015, the co entered into a definitive agreement to sell the Blue Fin Building, their principal executive offices in the U.K., for 415 million British pounds. The sale is expected to be consummated in the fourth quarter of 2015. Effective upon consummation of the sale of the Blue Fin Building, the Board of Directors has authorized common stock repurchases of up to $300 million and principal debt repayments and/or repurchases of up to $200 million.
• The headquarters move to NY is expected to result in $50 mln in annual savings beginning next year

6:16 am AES beats by $0.03, misses on revs; lowers FY15 EPS; guides FY16 EPS below; updates 2017-2018 guidance (AES) :

• Reports Q3 (Sep) earnings of $0.39 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.36; revenues fell 16.2% year/year to $3.72 bln vs the $5.39 bln Capital IQ Consensus.
• Co issues downside guidance for FY15, sees EPS of $1.18-1.25 from $1.25-1.35, excluding non-recurring items, vs. $1.27 Capital IQ Consensus Estimate.
• Co issues downside guidance for FY16, sees EPS of $1.05-1.15, excluding non-recurring items, vs. $1.30 Capital IQ Consensus Estimate. 
• The Company is expecting 12%-16% average annual growth in Adjusted EPS for 2017-2018, relative to the prior expectation of 6%-8% average annual growth off its prior 2015 Adjusted EPS guidance of $1.25-$1.35.
• Announcing a new $400 million share repurchase authorization that the Company expects to use opportunistically in conjunction with debt retirement to further strengthen credit metrics
• Reaffirming policy of increasing its dividend by 10% annually
• 5,782 MW of largely funded projects under construction are on track to come on-line through 2018, as previously expected .

6:15 am Lamar Advertising beats by $0.11, reports revs in-line (LAMR) :

• Reports Q3 (Sep) earnings of $0.89 per share, $0.11 better than the Capital IQ Consensus of $0.78; revenues rose 5.4% year/year to $350.7 mln vs the $348.37 mln Capital IQ Consensus.

6:13 am Ares Commercial Real Estate beats by $0.05; reaffirms FY15 EPS guidance (ACRE) :

• Reports Q3 (Sep) earnings of $0.33 per share, $0.05 better than the Capital IQ Consensus of $0.28.
• Co reaffirms guidance for FY15, sees EPS of $1.12-1.18 vs. $1.15 Capital IQ Consensus Estimate.

6:10 am USA Compression Partners beats by $0.06, beats on revs; raises guidance (USAC) :

• Reports Q3 (Sep) earnings of $0.21 per share, $0.06 better than the Capital IQ Consensus of $0.15; revenues rose 23.7% year/year to $70.5 mln vs the $66.63 mln Capital IQ Consensus. 
• Adjusted EBITDA rose 34.6% to $39.5 million in the third quarter of 2015 as compared to $29.3 million for the third quarter of 2014.
• Adjusted distributable cash flow increased 40.6% to $32.3 million
• Co is revising upward the following full-year 2015 guidance:
  • Adjusted EBITDA range of $147 million to $152 million
  • Adjusted distributable cash flow range of $113 million to $118 million.
• Fleet horsepower for third quarter 2015 increased by 16.1% over third quarter 2014
• "We have ordered approximately 220,000 horsepower of new compression units for delivery in 2015, of which we've taken delivery of approximately 195,000 horsepower through the first three quarters of the year," he said. "As we've previously discussed, we front loaded our capital spending this year, and as such, have completed over 90% of our spending for the year. Looking ahead, we have already ordered over 30,000 horsepower for delivery in 2016 and will continue to monitor the marketplace as we finish 2015 and move into next year."

6:09 am New Home beats by $0.03, beats on revs; guides FY15 EPS in-line (NWHM) :

• Reports Q3 (Sep) earnings of $0.27 per share, $0.03 better than the Capital IQ Consensus of $0.24; revenues rose 204.2% year/year to $87 mln vs the $71.17 mln Capital IQ Consensus. Homebuilding gross margin percentage was 13.8%, compared to 15.6% in the prior year period.
• Co issues in-line guidance for FY15, sees EPS of $1.20-1.35 vs. $1.34 Capital IQ Consensus Estimate. Co sees wholly Owned revenues of $250 - $270 million; sees fee Building revenues of $130 - $140 million

6:06 am Prestige Brands beats by $0.03, reports revs in-line; sees FY16 EPS at high end, sales at low end of range (PBH) :

• Reports Q2 (Sep) earnings of $0.60 per share, $0.03 better than the Capital IQ Consensus of $0.57; revenues rose 13.7% year/year to $206.1 mln vs the $207.98 mln Capital IQ Consensus, reflect continued strong consumption levels across the Company's core over-the-counter (:OTC) healthcare brands, continued growth in the international business, as well as contributions from the acquisitions of Insight Pharmaceuticals (Insight) and Hydralyte.
• Co issues in-line guidance for FY16, sees EPS at high end of $2.05-2.10 vs. $2.09 Capital IQ Consensus; lowers FY16 revs to +10-11% from +10-12% to recognize higher FX headwind.

6:05 am Ameresco misses by $0.03, beats on revs; narrows FY15 guidance (AMRC) :

• Reports Q3 (Sep) earnings of $0.09 per share, $0.03 worse than the single analyst estimate of $0.12; revenues rose 12.0% year/year to $189.1 mln vs the $168.15 mln two analyst estimate.
• Co issues in-line guidance for FY15, lowers top end of EPS to $0.16-0.20 from $0.16-0.24 vs. $0.20 single analyst estimate; raises bottom end of FY15 revs to $625-640 mln from $610-640 mln vs. $624.16 mln two analyst estimate.
• The guidance assumptions for Q4 are as follows: Gross margin of ~19%. In Q4, the Company expects to incur both cash and non-cash charges in conjunction with the certain restructuring activities.
• The Company has not completed all of the restructuring activity, and cannot yet disclose a firm estimate of the likely charges. However, the Company does expect to incur employee termination costs of $1 million to $1.5 million, which would reduce net income per diluted share to $0.14 to $0.17.

6:05 am Broadridge Financial beats by $0.06, reports revs in-line; reaffirms FY16 guidance (BR) :

• Reports Q1 (Sep) earnings of $0.33 per share, $0.06 better than the Capital IQ Consensus of $0.27; revenues rose 7.0% year/year to $594.7 mln vs the $597.88 mln Capital IQ Consensus.
• For FY16, the Company continues to anticipate:
  • Recurring fee revenue growth in the range of 10% to 12% and total revenue growth in the range of 8% to 10%
  • Adjusted Operating income margin of ~18.4%
  • Effective tax rate of ~34.8%
  • Adjusted Diluted earnings per share growth in the range of 8% to 12%
  • Free cash flows in the range of $350 million to $400 million
  • Recurring revenue closed sales in the range of $120 million to $160 million

6:02 am VEREIT and Golden Gate Capital partner in transactions that include more than $600 million of Red Lobster restaurants; GGC to acquire $204 mln in properties (VER) : Co and Golden Gate Capital announced that they have partnered in transactions including more than $600 million of Red Lobster restaurant properties owned by VEREIT. GGC acquired a $204 million pool of properties from VEREIT and, through a strategic partnership, GGC and VEREIT will opportunistically divest an additional $400 million of properties by executing single- or multi-unit dispositions at accretive valuations.

6:01 am Jones Lang LaSalle acquires Guardian Property Asset Management; terms not disclosed (JLL) :  

5:57 am Magna beats by $0.04, misses on revs; raises FY15 revs guidance (MGA) :

• Reports Q3 (Sep) earnings of $1.13 per share, $0.04 better than the Capital IQ Consensus of $1.09; revenues fell 7.1% year/year to $7.66 bln vs the $7.75 bln Capital IQ Consensus.
• Co raises guidance for FY15, sees FY15 revs of $31.3-32.6 bln (prior $30.9-32.6 bln) vs. $32.15 bln Capital IQ Consensus Estimate.
• Subject to approval by the Toronto Stock Exchange and the New York Stock Exchange, the Board of Directors approved a normal course issuer bid to purchase up to 40 million of Common Shares, representing approximately 9.9% of its public float of Common Shares. This normal course issuer bid is expected to commence on or about November 13, 2015 and will terminate one year later.

5:54 am Natl Hlth Investors beats by $0.01, beats on revs; raises FY15 FFO in-line (NHI) :

• Reports Q3 (Sep) adjusted funds from operations of $1.07 per share, $0.01 better than the Capital IQ Consensus of $1.06; revenues rose 31.0% year/year to $58.3 mln vs the $56.43 mln Capital IQ Consensus. Same-store RIDEA portfolio EBITDARM increased 4.7% QoQ.
• Co issues in-line guidance for FY15, raises adj FFO to $4.62-4.66 from $4.55-4.59 vs. $4.63 Capital IQ Consensus Estimate. 

5:51 am S&P futures vs fair value: +3.00. Nasdaq futures vs fair value: +8.50. :

5:51 am European Markets : FTSE...6391.26...-21.60...-0.30%.  DAX...10928.18...+82.90...+0.80%.

5:51 am Asian Markets : Nikkei...19116.41...+189.50...+1.00%.  Hang Seng...23051.04...-2.50...0.00%.

5:48 am On The Wires (:WIRES) :

• Cheetah Mobile (CMCM) announced it has entered into a supplemental agreement with Shenzhen Tencent Computer Systems, a subsidiary of Tencent Holdings Limited (TCEHY), which increases the annual cap for promotional services fees payable by Tencentand its subsidiaries and associates to Cheetah Mobile for the year ending December 31, 2015.
• Boeing (BA) and Korean Air today finalizedthe airline's order of 30 737 MAXs and two additional 777-300ER (Extended Range)jetliners valued at nearly $4 billion at current list prices. The airline also has options foradditional 737 MAXs as part of the order, which was previously announced as a commitment during the ParisAir Show in June.
• Silvercrest Asset Management Group Inc.'s (SAMG) Board ofDirectors approved the appointment of the Company's Chief Executive Officer andPresident, Richard R. Hough III, to the position of Chairman of the Boardeffective immediately.
• Vimicro International (VIMC) announced that it has called an extraordinary general meeting ofshareholders, to be held on December 15, 2015 to consider and vote on, amongother matters, the proposal to authorize and approve the previously announced agreement and plan of merger dated as of September 15, 2015, among theCompany, Vimicro China Limited and Vimicro China Acquisition Limited
• Accenture (ACN) is accelerating its research and development agenda in artificial intelligence across itsglobal network of Accenture Technology Labs, by opening the newest lab in Dublin and committing a significant portion of its global R&D capabilities, tohelp clients across industries integrate intelligent systems to improveoperations and create new growth opportunities.
• Marcus & Millichap (MMI) has named Ken Saywardchief information officer. Before joining Marcus & Millichap, Sayward was the head of global business applications for Colliers International

5:45 am Canadian Natrl Res beats by $0.19, beats on revs (CNQ) :

• Reports Q3 (Sep) earnings of CC$0.10 per share, CC$0.19 better than the Capital IQ Consensus of (CC$0.09); revenues rose 6508.7% year/year to CC$3.11 bln vs the CC$2.82 bln Capital IQ Consensus.
• "We look to maintain this positive momentum into 2016, with 2016 production volumes targeted at roughly the same level as in 2015. We currently anticipate 2016 cash flows to cover 2016 capital expenditures between $4.5 and $5.0 billion, which includes approximately $2.1 billion of Horizon expansion project expenditures. Importantly, we target to exit 2016 with Horizon production volumes at 170,000 bbl/d and the Phase 3 expansion well advanced toward completion in Q4/17. For 2017, Horizon expansion project expenditure levels are targeted between $1.0 and $1.3 billion, as we complete the Horizon expansion."
• Canadian Natural anticipates a 2016 capital program in the range of $4.5 billion to $5.0 billion, with approximately $2.1 billion allocated to Horizon Phase 2B and Phase 3 construction.
• Daily production was 848, 701 boe/d vs. 796,931 a year ago

5:32 am SpartanNash calls for redemption of all the outstanding $50 mln aggregate principal amount of 6.625% Senior Notes due 2016 (SPTN) : Notes called for redemption become due and payable on the Redemption Date at a cash redemption price of 101.65625% of the principal amount of the Notes, plus any accrued and unpaid interest to the Redemption Date.

5:15 am Orion Marine beats by $0.01 (in-line with the October 21 profit warning), misses on revs; guides FY15 EPS in-line, revs below consensus; guides FY16 EPS below consensus, revs in-line (ORN) :

Reports Q3 (Sep) loss of $0.27 per share, $0.01 better than the Capital IQ Consensus of ($0.28); revenues rose 28.1% year/year to $137.06 mln vs the $144.7 mln Capital IQ Consensus.

• Co issues guidance for FY15, sees EPS of ($0.35)-($0.30) vs. ($0.33) Capital IQ Consensus Estimate; sees FY15 revs of $460-480 mln vs. $484.36 mln Capital IQ Consensus Estimate.
• Co issues guidance for FY16, sees EPS of $0.30-0.40 vs. $0.51 Capital IQ Consensus Estimate; sees FY16 revs of $625-675 mln vs. $656.62 mln Capital IQ Consensus Estimate.
• "During the third quarter, we bid on approximately $682 million worth of opportunities and were successful on approximately $195 million. This represents a 29% win rate and a book-to-bill ratio of 1.18 times for the quarter. We currently have a combined $724 million worth of bids outstanding. Of this, approximately $262 million of the bids outstanding are related to the Heavy Civil Marine Construction segment with $462 million related to the Commercial Concrete Construction segment. In the Heavy Civil Marine Construction segment, we have been identified as low bidder on approximately $18 million. In our Commercial Concrete segment, we have also received award subsequent to the end of the quarter on projects totaling approximately $16 million."
• Backlog of work under contract as of September 30, 2015, was $404.1 million

5:09 am Mazor Robotics misses by $0.02, misses on revs (MZOR) :

• Reports Q3 (Sep) GAAP loss of $0.12 per share, $0.02 worse than the Capital IQ GAAP consensus estimate of ($0.10); revenues fell 18.4% year/year to $4.97 mln vs the $6.09 mln Capital IQ Consensus.
• "We entered the fourth quarter with a robust pipeline and we have received orders for two systems in the quarter to date. We continue to have ongoing discussions with hospital administrators, the pipeline remains solid and we are reaffirming our confidence that Mazor will sell more Renaissance systems in the second half compared to the first half of 2015."

4:53 am On The Wires (:WIRES) :

• Gevo (GEVO) announced that following the recent completion of successfulcompatibility tests, it will collaborate with ValvTect, a supplier of marinefuel additives, in bringing renewable isobutanol fuel blends to ValvTectbranded marinas.
• Singapore General Hospital and ThermoFisher Scientific (TMO) announced the establishment of a collaborativepartnership that will work to identify cancer genetic mutations linked withAsian populations on Thermo Fisher's Ion Torrent next-generation sequencingplatform.
• Steel Dynamics (STLD) confirmed Dept of Commerce preliminary countervailing duties against imports of corrosion-resistant steel from China and also accepting of the findings related to India and Italy. The company had anticipated minimal results for Taiwan and Korea. DOC found subsidy rates ranging from 26% to 236% against imports from China, the biggest source of corrosion-resistant steel imports into the United States in 2014. The Chinese companies with 236% duties will also have these duties applied retroactively by 90 days because of a preliminary affirmative critical circumstances finding by the DOC as the result of recent import surges from China. DOC will finalize its subsidy findings by the end of January 2016. 
  
• Basilea Pharmaceutica (Pending: BSLN) reported thatpreclinical data on its investigational clinical stage anti-cancer drugcandidate BAL101553 will be presented at the AACR-NCI-EORTC InternationalConference on Molecular Targets and Cancer Therapeutics in Boston, USA,November 5-9, 2015. The datademonstrate that BAL27862 (the active moiety of the prodrug BAL101553) hasanti-proliferative activity against glioblastoma stem-like cells. Furthermore,short-term treatment of mice bearing glioblastoma brain tumors with BAL101553was shown to provide a survival benefit.
• Staffing 360 Solutions (STAF) announced that it has completed the acquisition of the London-basedIT staffing firm, The JM Group. The acquisition closed on November 4, 2015. Theco's annualized revenue run-rate is now expected to exceed $170 million on a consolidated basis.
• InterOil Corporation (IOC) will increase its interest in two key licenses following the withdrawal ofPacific Exploration & Production Corporation (PEGFF) from Papua New Guinea.As a consequence of Pacific's withdrawal, InterOil will increase its interest in PRL 39, which contains the Triceratops discovery,and also in PPL 475, which contains the Raptor discovery.
• Abengoa (ABGB) has signedan extension to its operations and maintenance agreement with the Moroccan Powerand Drinking Water Office for the 472 MW Ain Beni Mathar solar-gas power plant.It is the first plant to use integrated solar combined cycle technology, whichcame into commercial operation in the world in 2010. The contract is worthapproximately 63 million.

4:50 am Interactive Data filed to withdraw its IPO prospectus following October's acquisition by IntercontinentalExchange (ICE) (:IDC) :  

4:48 am Harmony Gold misses by $0.06; beats on revs (HMY) :

Reports Q3 net loss of $0.09 per share vs ($0.03) Capital IQ consensus; revs increased 7% YoY to $276.4 mln vs $275.9 mln consensus.

• Quarter on quarter total gold production increased by 10% to 8 752 kilograms (281 385oz), largely due to an 8% improvement in underground tonnes milled and an 8% improvement in the underground recovered grade.

4:43 am Autohome beats by $0.02, reports revs in-line; guides Q4 revs below consensus (ATHM) :

• Reports Q3 (Sep) earnings of $0.35 per share, $0.02 better than the Capital IQ Consensus of $0.33; revenues rose 59.2% year/year to $141.39 mln vs the $140.13 mln Capital IQ Consensus.
• Co issues downside guidance for Q4, sees Q4 revs of $148.2-154 mln vs. $163.75 mln Capital IQ Consensus Estimate.

4:28 am Teekay Tankers misses by $0.07, beats on revs (TNK) :

• Reports Q3 (Sep) earnings of $0.30 per share, $0.07 worse than the Capital IQ Consensus of $0.37; revenues rose 142.6% year/year to $122.78 mln vs the $120.06 mln Capital IQ Consensus.
• "..our third quarter results were negatively impacted by a significantly heavier than normal drydocking schedule, which included the repositioning and scheduled drydocking of five of the Principal Maritime Suezmax tankers that delivered during the quarter, as well as the timing difference related to the issuance of new common shares early in the third quarter in connection with our recent acquisitions....During the fourth quarter to-date, crude spot tanker rates have strengthened and remained firm. We expect crude spot tanker rates to increase further for the remainder of 2015 and into the first quarter of 2016"
• As of September 30, 2015, the Company had total liquidity of $206.2 mln (comprised of $80.6 mln in cash and cash equivalents and $125.6 mln in undrawn revolving credit facilities).

4:25 am Teekay Shipping misses by $0.22, beats on revs (TK) :

• Reports Q3 (Sep) earnings of $0.04 per share, $0.22 worse than the Capital IQ Consensus of $0.26; revenues rose 24.8% year/year to $611.62 mln vs the $574.6 mln two analyst estimate.
• "Teekay Parent's free cash flow is supported primarily by the stable and growing cash flows received from our two master limited partnerships. Teekay LNG's and Teekay Offshore's diversified portfolios of long-term fee-based contracts, which total approximately $11.3 billion and $8.2 billion, respectively, of forward revenues, are not directly-linked to commodity prices and service our customers' oil production and oil and gas transportation needs."

4:21 am Teekay LNG Partners reports Q3 results (TGP) :

The co reported that revenues were -2.1% to $98.18 mln vs estimates for revs of $100.12 mln. During the third quarter of 2015, the Partnership generated distributable cash flow of $61.1 mln, compared to $64.2 mln in the same period of the prior year. The Partnership reported adjusted net income attributable to the partners of $37.1 mln for the quarter ended September 30, 2015, compared to $46.7 mln for the same period of the prior year. As of September 30, 2015, the Partnership had total liquidity of $206.3 mln. Subsequent to September 30, 2015, the Partnership secured a new $150 mln unsecured revolving credit facility to fund future capital commitments, which is expected to be completed in November 2015.

• "The Partnership generated stronger than expected distribution coverage in the third quarter, primarily due to higher than expected revenues from our Exmar LPG joint venture. Teekay LNG's distributable cash flow remains stable and growing. The Partnership's diversified portfolio of fee-based contracts, with no direct link to commodity prices, comprises fixed forward revenues of ~$11.3 bln."

4:18 am Teekay Offshore reports Q3 results (TOO) :

Revenues increased 24.4% y/y to $285.89 mln vs. estimates for $306.3 mln. During the third quarter of 2015, the Partnership generated distributable cash flow of $58.8 million, compared to $45.2 million in the same period of the prior year. The Partnership reported adjusted net income attributable to the partners(1) of $32.1 million for the quarter ended September 30, 2015, compared to $28.8 million for the same period of the prior year. As of September 30, 2015, the Partnership had total liquidity of $305.3 million (comprised of $251.1 million in cash and cash equivalents and $54.2 million in undrawn credit facilities).

• "Despite the current weakness in global energy markets, Teekay Offshore's distributable cash flow remains relatively stable and growing. The Partnership's diversified portfolio of fee-based contracts, which is servicing our customers' oil production requirements and with no direct link to oil prices, comprises fixed forward revenues of approximately $8.2 billion."  

4:12 am AstraZeneca beats by $0.03, misses on revs; raises FY15 EPS above consensus, revs above consensus (AZN) :

• Reports Q3 (Sep) earnings of $1.03 per share, $0.03 better than the Capital IQ Consensus of $1.00; revenues fell 6.8% year/year to $5.85 bln vs the $5.95 bln Capital IQ Consensus.
• Co issues upside guidance for FY15, sees EPS of mid-to-hi single digit increase (vs $4.28 LY) vs. $4.16 Capital IQ Consensus Estimate (vs prior guidance of low single-digit percent increase versus the prior year)
• Co issues upside guidance for FY15 revs to be in-line with LY (~$26.1 bln) vs. $24.4 bln Capital IQ Consensus Estimate (vs prior guidance of low single-digit percent decline versus the prior year).

4:07 am Grupo Aeroportuario reports that terminal passenger traffic at its 13 airports increased 12.8% in October (OMAB) : Domestic traffic increased 12.2%, and international traffic increased 17.5%. Of total October traffic, 98.2% was commercial aviation and 1.8% was general aviation.

4:04 am Iron Mountain reports that the Australian Competition and Consumer Commission has released a Statement of Issues related to its proposed acquisition of Recall Holdings (IRM) : Iron Mountain states the Statement of Issues is a normal part of the ACCC process and it is designed to seek industry views and further information on certain competition issues that have arisen from the ACCC's market inquiries to date. The Statement of Issues is not a final decision. It provides the ACCC's preliminary views on the proposed acquisition. The ACCC has commenced a public consultation process in respect of the Statement of Issues and invites further submissions from interested parties. The ACCC has indicated that it expects to announce its final decision in respect of the transaction on December 15, 2015. The transaction is still expected to close in the first quarter of 2016.

3:54 am On The Wires (:WIRES) :

• Alliance HealthCare Services (AIQ) announced a new joint venture partnership with PRC Associates. PRC is a provider of interventional pain management services in Florida, delivered at eight locations in Central Florida and the Palm Coast.
• Dassault Systmes (DASTY) announced its partnership with bluenove Group. The cooperation will transform the way in which open innovation can be delivered and accelerated to help companies invent products, services and solutions.
• Telenor (TELNY) Board of Directors has assigned Deloitte Advokatfirma to perform a review of Telenor's handling and oversight of the minority ownership in VimpelCom (VIP).
  

3:41 am Evercore prices secondary offering of 5,454,545 shares of common stock, all sold by Mizuho Bank (MFG) at $55.00 per share (EVR) :  

3:39 am Bona Film makes $235 mln investment in TSG Entertainment Finance (BONA) : Bona Film Group announced that it has made a $235 million investment in TSG Entertainment Finance. TSG is a film finance entity working with Twentieth Century Fox to finance primarily live action films.

3:22 am Sanofi-Aventis and and Hanmi sign license agreement to develop a portfolio of experimental diabetes treatments; Hanmi to receive an upfront payment of 400 million (SNY) :

Sanofi and Hanmi Pharmaceutical announced a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.

• Under the terms of the agreement, Hanmi will receive an upfront payment of 400 million and is eligible for up to 3.5 billion in development, registration and sales milestones, as well as double digit royalties on net sales.
• Sanofi will obtain an exclusive worldwide license to develop and commercialize 1.) efpeglenatide, a late-stage long-acting glucagon-like peptide-1 receptor agonists; 2.) a weekly insulin and 3.) a fixed-dosed weekly GLP-1- RA/insulin drug combination.

3:18 am Cellcom Israel acquires Golan Telecom for NIS1.17 bln (CEL) :

Cellcom Israel announced it entered an agreement with Golan Telecom for the purchase of 100% of the shares of Golan, an Israeli cellular operator, for the sum of NIS1.17 billion.

• Golan is one of the four other Mobile Network Operators operating in Israel in addition to Cellcom Israel. Golan is expected to end 2015 with total revenues exceeding NIS 500 million.
• The Purchase Price represents an Enterprise Value, or EV2 of NIS 1 billion for Golan and EV/Adjusted EBITDA multiple of approximately 5.0, based on Golan's forecasted Adjusted EBITDA for 2015

3:15 am Amedisys reports EPS in-line, beats on revs (AMED) :

• Reports Q3 (Sep) earnings of $0.34 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.34; revenues rose 8.7% year/year to $326.5 mln vs the $311.76 mln Capital IQ Consensus.

3:08 am Travelport Worldwide upsizes offering by co and selling shareholders and prices 10 mln common shares; price undisclosed (TVPT) :  

3:06 am Sabre prices 30 mln shares of common stock by selling shareholders at a price of $29.27 per share (SABR) : Offering by existing stockholders affiliated with TPG Global and Silver Lake Management Company

3:04 am Royal Gold misses by $0.12, misses on revs (RGLD) :

Reports Q3 EPS, ex-items of $0.17 per share vs $0.29 Capital IQ consensus; revs increased 7% YoY to $74.1 mln vs $89.8 mln consensus

• Co recorded the second consecutive quarter of record volume at 65,868 gold equivalent ounces in the first quarter of fiscal 2016, up 22% from the year-ago quarter. Revenue of $74.1 million reflected a 7% increase over the prior year quarter.
• Physical gold inventory held on the balance sheet and not reflected in revenue increased to 11,500 ounces during the first quarter, a 117% increase over the physical gold inventory of 5,300 ounces as of June 30, 2015.

3:00 am Sunoco LP beats by $0.19, beats on revs; raises distribution by 7.5% over Q2 (SUN) :

• Reports Q3 (Sep) earnings of $0.81 per share, $0.19 better than the Capital IQ Consensus of $0.62; revenues rose 243.9% year/year to $4.49 bln vs the $4.08 bln Capital IQ Consensus.
• Distribution increased 7.5% versus 2Q 2015 and an ~37 percent increase versus the prior year period
• Acquisition of Susser Holdings Corporation in 3Q contributed to strong earnings and increased SUN's exposure to high-growth retail markets
• Distributable cash flow coverage ratio of 2.0x for 3Q
• SUN's gross capital expenditures for the third quarter excluding acquisitions totaled $94.5 million.

2:39 am Randgold Resources reports Gold production for the quarter was 305,288 ounces, up more than 5,000 ounces on Q2 (GOLD) :

Co reports production to a new record level in the third quarter of the year on the back of a steady all-round operational performance while stepping up exploration programmes designed to find its next world-class discovery as well as to expand its existing reserves.

• Gold production for the quarter was 305 288 ounces, up more than 5 000 ounces on Q2, with Kibali and Morila doing exceptionally well. Heavy rains in Mali resulted in a pump system failure at Loulo, which temporarily cut off access to the high grade ore sections underground at Yalea.
• This resulted in lower than forecast grades and production, impacting on total cash cost per ounce, which rose to $699/oz (Q2: $684/oz). A further drop in the gold price also depressed profits, which were $48.8 million against the previous quarter's $59.2 million.
  

2:25 am On The Wires (:WIRES) :

• Iron Mountain (IRM) reports that the Australian Competition and Consumer Commission as expected has released a Statement of Issues related to Iron Mountain's proposed acquisition of Recall Holdings by way of scheme of arrangement. Transaction still expected to close in first quarter of 2016.
• Princess Cruises, a unit of Carnival (CCL) launched its biggest sale of the year called "Cruise Deals and Air Steals," offering cruise vacation deals and airfares that are among the lowest currently available.